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PROBING THE ANTI-CANCER MECHANISM OF SELENITE: A 
METABOLIC APPROACH 
Alex Belshoff 
June 19, 2013 
 
The following dissertation was aimed at characterizing the metabolic disruptions 
that occur with selenite treatment in human lung cancer. Specifically, the 
pathways of glycolysis, TCA cycle, nucleotide metabolism, pentose phosphate 
pathway, hexosamine biosynthetic pathway, and glutaminolysis were examined 
thoroughly. A stable isotope-resolved metabolomic (SIRM) approach utilizing the 
tracers 13C6-glucose and 13C5,15N2-Gln was employed in order to trace the flow of 
atoms through the metabolic network. By utilizing this approach and a 
combination of NMR and MS analyses, the metabolic pathways perturbed by 
selenite were reconstructed based on measured isotopologues and isotopomers 
and known biochemical reaction mechanisms. These methods were employed in 
both cell-based and individualized ex vivo lung cancer tissue models developed 
from an ongoing NSCLC patient study. In the A549 cell model, glycolysis was 
upregulated by selenite treatment with a corresponding decrease in flux through 
the TCA cycle and increase in flux through lactate dehydrogenase. These effects 
were propagated through nucleotide synthesis by inhibiting the rate of carbon
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 and nitrogen incorporation into nucleobases. Furthermore, UDP-GlcNAc 
synthesis was diminished by selenite treatment, particularly in terms of its uracil 
subunitand acetyl group incorporation. These findings were specific to cancer 
cells and not observed in non-transformed NHBE cells and were recapitulated in 
the patient data. The KGA splice variant, GAC, was greatly reduced by selenite 
treatment, which was consistent with the metabolic data and reduction in 
glutaminase activity. Again, this effect was not observed in NHBE cells. 
Proliferation of A549 cells was at least partially restored upon supplementation of 
selenite-treated cells with Glu, the product of the glutaminase reaction, validating 
the importance of glutaminase in selenite-mediated cytotoxicity, including the 
synthesis of glutathione for detoxifying excess ROS. Finally, findings from the 
tissue slice data suggested that selenite induced a decrease in the synthesis of 
glycogen. The brain form of glycogen phosphorylase (PYGB) was suppressed 
using shRNA in order to characterize the metabolic consequences. Glycogen 
was identified as an important source of fuel for A549 cells, since suppression of 
PYGB resulted in reduced growth and colony formation accompanied by 
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It is estimated that 1.66 million people in the US will be diagnosed with some 
form of cancer and that 580,000 people will die from cancer in 2013 [1]. The 
current risk for a cancer diagnosis during one’s lifetime is approximately 40%, 
which is a reduction of only 0.9% and 0.3% for men and women, respectively, 
from 1999-2010 [1]. Furthermore, the reduction in cancer deaths for this time 
period decreased by only 1.5% [1]. In the US, death from cancer is currently the 
second highest cause of death behind only cardiovascular disease, but is above 
chronic obstructive pulmonary disease (COPD), stroke, and accidents [2]. The 
problem is particularly severe for lung cancer, which causes the greatest number 
of cancer deaths worldwide with an estimated 228,000 diagnoses and 159,000 
deaths in the US alone for 2013 [3]. Currently lung cancer is the 3rd most 
common form of cancer behind breast and prostate, despite decreases in its 
prevalence and death rate of 2.6% and 2.2%, respectively, from 2005-2010 [1]. 
However, these reductions are mostly due to a decrease in the prevalence of 
smoking with only small improvements in lung cancer diagnosis or management. 
Obviously, smoking is a huge environmental risk factor of lung cancer that 
increases with number of cigarettes smoked and the duration of the smoking 
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history. Cessation remains one of the most effective means of prevention and 
reduces one’s risk of developing lung cancer approximately 3-fold [4]. In a study 
following men born in the 1920’s, cancer risk was reduced to that of a non-
smoker if cessation was achieved by age 30 and was reduced by half if it was 
achieved by the age of 50 [4]. 
 Lung cancer is a particularly severe issue for Kentucky, which leads the 
nation in incidence and deaths [1]. In addition, Kentucky carries the 2nd highest 
incidence rate for all cancer diagnoses and deaths [1]. Furthermore, lung cancer 
related medical expenditures are a huge burden on the healthcare system with 
an estimated direct cost of 12.1 billion dollars in 2010, corresponding to 
approximately 10% of total cancer-related expenses [5]. Clearly, lung cancer 
research is of vital importance not only to improve management, but also to 
improve diagnostic capabilities.  
 
1.2 Current practices in lung cancer diagnostics and 
management  
The long-term goal of applying SIRM in lung cancer research is both to aid in 
improved diagnostics and therapeutics for better management of lung cancer. 
The cure rate for lung cancer remains woefully low despite new management 
strategies for other types of cancers. These poor outcomes are largely due to 
late diagnoses where surgery is not an option due to significant metastasis. Only 
15% of tumors are localized and operable at the time of diagnosis, which carries 
the best 5-year survival rate of 53.5% [1]. However, 5-year survival drops 
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precipitously to 26.1% and 3.9% for regional and distant diagnoses, respectively 
[1]. Distant metastasis comprises the majority of diagnoses at 57% [1]. 
Adenocarcinomas of the lung carry the best prognosis with a 5-year survival rate 
of approximately 60% for localized disease; however small-cell cancer prognosis 
is poor even with a localized diagnosis (20.1%) [6]. The squamous and large cell 
subtypes comprise roughly 20% and 5% of lung cancers, respectively, and there 
is discrepancy over whether the prognosis of these subtype differ significantly 
from adenocarcinoma [1].  
 
1.2.1 Diagnosis.  
As stated previously, much of the problem underlying poor lung cancer 
survival is late diagnosis. When symptoms present, the tumor has usually 
distantly metastasized, and screening historically has been largely ineffective. 
However, a risk-benefit analysis of the ongoing national lung cancer screening 
trial (NLST) indicated that low-dose computed tomography (LDCT) screening 
was beneficial for a select group of patients [7]. Therefore, the American Cancer 
Society recently issued recommendations for annual screening of people aged 
55-75 years old who are current smokers or who have quit within the past five 
years. 
Diagnosis also involves a thorough evaluation of tumor stage that 
incorporates the tumor size, invasion, number of lymph nodes involved, and 
presence or absence of metastasis. This step is crucial in order to determine 
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prognosis as well as surgical candidacy since surgery generally yields better 
outcomes than radiation or chemotherapy.  
NSCLC is staged according to the recently revised TNM staging system 
laid out by Goldstraw et. al [8]. Stage I disease is diagnosed when the primary 
tumor size is up to 5 cm in diameter with minimal invasion no further than the 
main bronchus. No regional lymph node involvement or distant metastasis can 
be present for this stage. Tumors greater than 7 cm in diameter are included in 
stage II disease that have more extensive invasion and involvement of regional 
lymph nodes not extending to the mediastinum, but without distant metastasis. 
Both stage III and IV disease can involve primary tumors of any size with 
extensive invasion and regional lymph node involvement; however, stage IV 
includes distant metastasis. Accurate staging involves requires diligent surgical 
dissection as well as proper histopathological examination and is essential for 
prognosis and management. 
This staging approach has recently been suggested and is in the process 
of being implemented for SCLC. Historically SCLC was categorized into either 
limited or extensive disease, which essentially referred to the presence or 
absence of distant metastasis. The more detailed TNM staging system has been 
validated for SCLC to improve prognostic value; however, management has 






Lung cancer treatment is dependent on the stage at the time of diagnosis 
as well as other general health factors of the patient that govern surgical 
candidacy. Also, the treatment plan is typically defined for non-small cell lung 
cancer (NSCLC) or small-cell cancer (SCC). For early stage (I and II) tumors 
surgical resection, if possible, is the standard of care [9]. Lobectomy is commonly 
done; however, recent evidence suggests that sublobar (e.g. wedge) resection 
provides comparable outcomes. The standard of care for early stage inoperable 
tumors is radiotherapy (RT), but has poorer outcomes (5-year survival 15-48%). 
However, the use of stereotactic body RT (SBRT) is increasing for these 
patients, as it yields better outcomes with substantially less toxicity for 
surrounding tissues. 
For advanced stage tumors, surgery is generally not an option, and 
combined chemoradiotherapy is typically used as it yields better outcomes than 
chemotherapy or radiotherapy alone. However, research is ongoing to determine 
whether induction chemotherapy, i.e., shrinking the tumor mass before surgery, 
may benefit a select patient population. For late stage NSCLC, platinum (Pt) 
based chemotherapy is generally adopted. Bevacizumab, a VEGF binding drug 
that inhibits angiogenesis, has also been recently combined with Pt-based 
therapy to achieve better outcomes. There are also some drugs that are used for 
tumors containing specific mutations. These include Crizotinib and Erlotinib, 
which are ALK kinase and tyrosine kinase inhibitors, respectively. 
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Finally, SCLC is typically managed with combined chemoradiotherapy for 
limited disease (e.g., etoposide/cisplatin with radiotherapy) and chemotherapy 
alone for extensive disease; however, these cancers carry a particularly grim 
prognosis despite ongoing research. 
 
1.3  Selenium nutrition and anti-cancer efficacy 
1.3.1 Nutrition and toxicity 
Selenium is an essential micronutrient and is incorporated into the ‘21st’ 
amino acid, selenocysteine [10]. Natural foods rich in selenium include Brazil 
nuts, seafood, and organ meats, among others [11]. Most of these natural food 
sources contain organic seleno-compounds such as selenomethionine as the 
predominant selenium species. The composition of inorganic selenium such as 
selenite and selenate in soil has large regional variation, which is propagated into 
organic forms such as selenomethionine through plant metabolism [12]. Selenite 
and selenate as well as organic forms are also available in the form of nutritional 
supplements. Selenium is utilized primarily in the redox reactions of enzymes like 
glutathione peroxidase and thioredoxin reductase by functioning similarly to a 
thiol. Selenium deficiency can lead to a constellation of symptoms including 
cardiomyopathy, weakened immune response, thyroid abnormalities, and bone 
deformities [13, 14]. Kashin-Beck disease is a well-characterized selenium 
deficiency endemic to China that involves cardiovascular disease and bone 
deformities [15]. However, selenium compounds can also be toxic at high doses 
(selenosis) and leads to brittle nails, hair, and skin abnormalities in humans due 
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to chronic overconsumption [16]. Selenosis is typically more of a problem in 
livestock than in humans. 
 
1.3.2 Selenium compounds possess anti-cancer activity 
 Selenium has a long history in cancer research as both a 
chemopreventive and chemotherapeutic agent. A large number of organic and 
inorganic seleno-species exist, such as methylseleninic acid (MSA) or selenite, 
which are cytotoxic to cancer cells. It is important to differentiate the various 
seleno-compounds outside of the umbrella term, selenium, due to a large 
variation in anti-cancer and chemopreventive efficacy. MSA has been studied 
extensively in prostate cancer and has been linked to decreased expression of 
prostate specific antigen [17-19]. Apoptosis has also been observed for prostate 
cancer cells treated with MSA [20]. Selenite also induces apoptosis in cancer 
cells including lung adenocarcinoma A549 cells and rodent models [21]. 
Recently, selenite was shown to cause ROS mediated autophagy in A549 cells 
by Park et al. [22]. Fan et al. has demonstrated the use of stable isotope-
resolved metabolomics (SIRM) combined with transcriptomics for probing 
metabolic alterations caused by selenite [23] 
 Despite these findings, however, the mechanism behind selenite toxicity is 
only partially understood. The prevailing theory of selenite toxicity involves 
successive reductions of selenite, eventually to some selenide species, 
generating toxic ROS in a process that causes damages to DNA and other cell 
machinery leading to death [24, 25].  
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1.3.2.1 Chemopreventive clinical trials 
 Selenium supplementation has been the subject of several clinical trials 
that yielded mixed results. The double-blind clinical trial by Clark et al. showed a 
statistically significant decrease in prostate cancer incidence with a selenized 
yeast supplementation [26]. Selenized yeast comprised of a mixture of selenium-
containing compounds. Unfortunately, the large scale SELECT trial (selenium 
and vitamin E cancer prevention trial) was prematurely terminated due to slightly 
increased cancer incidence with selenium supplement among the participants 
(reviewed in [27]). These results were disappointing; however, they are difficult to 
interpret due to the choice of the selenium agent, selenomethionine (SeM). SeM 
alone has very low cytotoxicity based on our findings and its cytoxicity is 
enhanced only when combined with the methionine lyase treatment, which was 
missing in the SELECT trial [28]. Therefore, further mechanism-based research 
is necessary in order to determine the optimal choice of selenium-based 
chemoprevention and/or therapy. 
 
1.4  Cancer is a metabolic disease 
1.4.1 The Warburg effect 
Historically, altered metabolism in cancer was established in the early 1920’s 
by Warburg [29]. In an elegant experiment, he demonstrated that even under 
normoxic conditions, the rate of glucose utilized by tumor tissue for lactic 
fermentation was ten times that used for aerobic respiration. Glycolytic 
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stimulation, i.e., the “Warburg effect”, has since been established as a hallmark 
of human tumors. Warburg actually postulated that stimulated glycolysis was the 
fundamental origin for tumorigenesis; however, the Warburg effect is now 
considered as one of the many metabolic consequences of accumulated 
mutations that enable the anabolic and energetic requirements for tumor growth.  
 
1.4.1.1 Clinical manipulations of the Warburg effect 
The Warburg effect is so prevalent among cancers that it is routinely used for 
cancer diagnostics by measuring the uptake of 2-deoxy-2-18F-D-glucose into 
suspected tumor tissues using positron emission tomography (PET) scanning. 
Increased rate of glycolysis has also been studied as a potential target for 
chemotherapy. 2-deoxyglucose is a hexokinase inhibitor that showed promise 
pre-clinically; however, the clinical trial yielded disappointing results [30]. 
Recently, 3-bromopyruvate (3BP) has been investigated in in vitro and in vivo 
experiments [31]. 3BP has shown low non-cancer toxicity and high selectivity for 
the inhibition of glyceraldehyde 3-phosphate dehydrogenase. Furthermore, the 
potent 6-Phosphofructo-2-kinase (PFKB3) inhibitor, PFK15, has generated very 
favorable results and is entering phase I clinical trials [32]. 
 
1.4.2 Tumors require increased anabolism and favorable energetics for 
growth 
 In order to sustain the rapid and uncontrolled growth that defines cancer, 
tumor cells need to increase their anabolism. By utilizing tracer-based 
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experimental design, Fan et. al. have shown that non-small cell lung cancer 
(NSCLC) tumors possess increased rates of glycolysis, Krebs’ cycle activity, 
pyruvate carboxylase (PC) activity, and nucleotide synthesis [33]. Increased flux 
through these pathways is vital to generating lipids, reducing equivalents, amino 
acids, and nucleotides necessary for new biomass production. The high rate of 
nucleotide synthesis that must occur to generate nucleic acids for rapidly growing 
cancer cells has led to the use of anti-metabolites such as thioguanine, 5-
fluorouracil, and methotrexate as chemotherapeutics. 
 
1.4.2.1 Altered metabolism is caused in part by the loss of tumor-
suppressor genes and the activation of oncogenes 
 Changes of metabolic regulation in human cancer have been an important 
focus of biomedical research and have been shown to be induced by a 
combination of genetic mutations and altered expression of transcriptional 
factors. These factors include increased transcription of MYC, increased activity 
of the transcription factor NF-κB, the protein kinase AKT, and stimulation of the 
mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase 
signaling pathways, among many others [34]. For glycolysis in particular, a 
combination of the loss of the tumor suppressor gene phosphatase and tensin 
homolog (PTEN) and activation of AKT and mTOR signaling cascades increases 
hypoxia-inducible factor 1α (HIF-1α) activity. HIF is stabilized under hypoxic 
conditions and positively regulates nine out of the 10 enzymes of glycolysis [35]. 
Also associated with elevated HIF-1 activity is the increase in glucose 
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transporters (GLUTs) to supply accelerated glycolysis [36]. Interestingly, many 
tumors also express the fetal M2 form of pyruvate kinase (PKM2). PKM2 binds to 
tyrosine-phosphorylated proteins, which in turn removes the positive regulation 
imposed by fructose-1,6-bisphosphate [37]. These events have the effect of 
diverting glucose for anabolic processes such as nucleotide metabolism by 
increasing the flux through the pentose phosphate pathway.  
 Gln is another essential nutrient for rapidly growing tumors as 
glutaminolysis is an important anapleurotic input for the TCA cycle and 
regeneration of anabolic precursors. Gln is converted to Glu enzymatically via 
glutaminase (GLS), which is up-regulated by expression of the proto-oncogene 
MYC [38]. Gln consumption is often increased in tumors and glutaminase (GLS) 
inhibition has been shown to induce apoptosis in kidney and lung cancer cells, 
which overexpress MYC to drive GLS expression [39].  
 
1.4.2.2 Mutations of specific metabolic enzymes characterize certain 
familial cancers 
 Interestingly, several familial cancers are associated with deficiencies of 
the TCA cycle enzymes fumarate hydratase (FH) or succinate dehydrogenase 
(SQR). Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is 
characterized by a germline mutation and loss of function of the gene expressing 
FH, followed by a profound rearrangement of TCA cycle metabolism [40]. SQR 
deficiency, again caused by germline mutation, is associated with both renal 
cancer and gastrointestinal stromal tumors (GIST) [41].  
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1.4.3 O-GlcNAc modification of protein targets is increased in cancers 
 Uridine diphospho-N-acetyl glucosamine (UDP-GlcNAc) is a product of the 
hexosamine biosynthetic pathway (HBP) that is used in the synthesis of 
glycosaminoglycans, proteoglycans, and glycolipids [42]. UDP-GlcNAc is also the 
substrate for O-GlcNAc transferase (OGT), which catalyzes the post-translational 
modification of Ser and Thr residues in certain proteins [43, 44]. The expression 
of OGT is increased in a variety of cancers including lung that correlates with 
increased post-translational modification of protein targets [45, 46]. Furthermore, 
targets are often co-regulated via phosphorylation with either synergistic or 
competitive effects [47, 48]. These two modes of regulation are dynamic and can 
even occur on the same residue.  
 UDP-GlcNAc biosynthesis is complex and incorporates intermediates from 
glycolysis, the PPP, TCA cycle, glutaminolysis, and nucleotide synthesis. 
Therefore, O-GlcNAcylation has been described as a nutrient sensor and 
appears to regulate phosphofructokinase (PFK) by diverting glucose carbon 
through the PPP under hypoxic conditions [49]. Interestingly, glucose starved 
cancer cells maintain flux through the HBP and synthesis UDP-GlcNAc by 
utilizing carbon from glycogen [50]. Other targets of OGT include OGT itself, 
MYC, p53 and histones, among many others [51-54]. However, the functional 
significance of the majority of these events is unclear. 
 Elucidation on the synthesis of UDP-GlcNAc from glucose and Gln is 
essential to understanding upregulation of O-GlcNAcylation in lung cancer . 
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Incorporation of glucose carbon into UDP-GlcNAc has been modeled by 
Moselely et al. and this pathway is one focus of this study[55]. 
 
1.5  Rigorous analysis of the metabolic network requires a 
systems-biochemical approach 
 In order to ascertain the breadth of metabolic changes that is induced by 
either cancer transformation or a stressor such as an anti-cancer agent, one 
must utilize an approach that is able to simultaneously measure the multitude of 
metabolites that participate in many pathways.  
 
1.5.1 Stable isotope-resolved metabolomics (SIRM) 
SIRM is an approach that utilizes a tracer-based experimental design in 
order to measure the incorporation of stable isotopes into metabolites. By 
utilizing tracers like 13C6-glucose or 13C5,15N2-Gln, one can trace the flow of 13C 
and 15N through glycolysis, PPP, HBP, TCA cycle, nucleotide biosynthesis, lipid 
biosynthesis, and glutaminolysis by measuring the different combinations of 
mass isotopologues or positional isotopomers that are generated for a given 
metabolite (Figs. 2.6, 2.14, 2.18, 4.15). Isotopolgues and positional isotopomers 
both refer to structures that differ in isotopic composition; however, positional 
isotopomers refers to the positional location of the isotope, e.g., 13C1-lactate has 
three distinct positional isotopomers. One can then begin to reconstruct the 
metabolic network and assess flux through specific pathways. By understanding 
which pathways are affected by a given stressor, one can then follow up with 
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more specific and complimentary analyses such as enzymatic activity assays, 
immunoblot, or qPCR in order to determine why and how a pathway is altered. 
The use of stable isotopes offers several important advantages over 
radioisotopes, including elimination of biohazard risk and ready detection by both 
NMR and MS. The incorporation of stable isotopes into a metabolite will not 
significantly alter its enzymatic transformation with respect to an unlabeled 
metabolite. Although the kinetic isotope effect on enzyme reaction rate can occur 
for different isotopes, this effect is largely negligible in 13C or 15N-based SIRM 
because these isotopes have small relative mass change with respect to their 
natural abundance atoms. Furthermore, the bond-breaking steps are usually not 
rate-limiting within a pathway.  
Fan et al. have utilized SIRM extensively to characterize metabolic 
alterations in lung cancer [33, 55-60]. The use of nuclear magnetic resonance 
(NMR) and mass spectrometry (MS) technologies are essential for SIRM and 
offer complementary analyses. Nuclei such as 13C and 15N are observable by 
NMR to provide structural information such as the position(s) of a heavy atom 
within a give metabolite (isotopomer) based on the spin coupling patterns, 
covalent linkage, and chemical shift information obtainable from NMR analyses. 
MS readily differentiates different isotopologues due to their mass differences. 
Furthermore, with the advent of Fourier transform-ion cyclotron resonance-mass 
spectrometry (FT-ICR-MS), one can distinguish the tiny mass difference between 
13C and 15N (e.g. 13C1,15N0 and 13C0,15N1) labeled species due to ultra-high mass 
resolution and accuracy.  
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Finally, one must not overlook the importance of bioinformatics for 
systems-biochemical approaches. The enormously rich data sets coupled with 
high-throughput analysis generated from metabolomic investigation make 
efficient bioinformatics essential to data analysis for generating meaningful and 
comprehensive conclusions or new hypotheses. 
 
1.6  Rationale for this study 
This study aims to test the hypothesis that the anti-cancer mechanism of 
selenite can be elucidated, at least in part, by a thorough and rigorous metabolic 
approach. Lung cancer is an important focus of study due to its prevalence and 
high lethality worldwide, and especially in Kentucky. Metabolic reprogramming 
elicited by oncogenic transformations is increasingly apparent in various types of 
cancer. Thus a systematic metabolic approach utilizing SIRM is expected to 
advance understanding in the diagnosis and management of lung cancer by 
uncovering key reprogrammed events, which then can be targeted for therapy or 
help uncover early detection markers. The use of individualized ex vivo lung 
cancer tissues adds a translational element to this investigation and can offer an 
exciting view of cancer metabolism from actual patients. Selenite is an excellent 
candidate to probe lung cancer metabolism given its history of anti-cancer activity 
and potential for chemoprevention. Further research into selenite’s mechanism of 
action is imperative to help clarify the recently failed SELECT trial. 
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CHAPTER 2-SELENITE INDUCES CANCER-
SPECIFIC CHANGES IN METABOLISM 
2.1 Introduction 
An emerging trademark of human tumors is increased O-linked 
modification of proteins by N-acetylglucosamine (O-GlcNAcylation) [51]. 
Increased O-GlcNAcylation has been observed and reported in lung, colon, and 
breast cancers in both pure cell culture and human tumors [45, 46, 61]. The 
expression of the transfer enzyme responsible for this post-translational 
modification, O-linked N-acetylglucosamine transferase (OGT) is increased in 
these tissues and thus is likely responsible for the observed increase in GlcNAc 
modification [45]. However, what has been lacking in these investigations is a 
detailed study of the biosynthesis of uridine diphospho-N-acetylglucosamine 
(UDP-GlcNAc), the GlcNAc donor and substrate of the transferase, in human 
lung cancer associated-upregulation of GlcNAc modification.  
UDP-GlcNAc is the nucleotide hexosamine that contributes GlcNAc for O-
linked glycosylation. The synthesis of UDP-GlcNAc is a complex processes that 
comprises multiple pathways including the pentose phosphate pathway, 
hexosamine biosynthetic pathway, glutaminolysis, nucleotide biosynthesis, 
Krebs’ cycle, and glycolysis. The connection of this metabolite to glucose and 
glutamine metabolism has established UDP-GlcNAc synthesis as a nutrient 
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sensor [47, 49, 62, 63].  As such, UDP-GlcNAc biosynthesis, including its 
contributing metabolic pathways, needs thorough SIRM-based analysis to 
determine the regulatory mechanisms underlying synthesis of this important 
metabolite.   
The utility of SIRM for the analytical dissection of cancer transformed lung 
metabolism has been well established [33, 56, 58]. Furthermore, UDP-GlcNAc 
biosynthesis in prostate cancer cells was previously modeled using a non-
steady-state algorithm and a SIRM based approach by Moseley et al. [55]. Here, 
I expanded upon previous work reported by Fan et al. on metabolic alterations 
induced by the anti-cancer agent selenite [60]. Our goal was to uncover a more 
detailed mechanistic understanding of selenite-induced anti-cancer activity by 
determining the time course enrichment of glucose and Gln derived metabolites 
associated with the UDP-GlcNAc biosynthetic network and comparing these 
profiles to an immortalized normal human bronchial epithelial (NHBE) cell line. 
 This approach was then repeated in parallel experiments utilizing NSCLC 
surgical patient tumor and adjacent benign tissue. These individualized lung 
cancer models offer a more realistic interpretation of the metabolic changes that 
occur with exposure to selenite because they contain much of the tumor 
infrastructure, including stromal cells as well as potentially tumor-suppressive 
immune cells. Furthermore, these experiments are derived from actual NSCLC 
patients and are thus representative of the variability of early-stage operable lung 
cancer. However, the heterogenous cell population of this model is likely to 
produce a more mixed set of results than those obtained from traditional 
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monolayer cell culture. But, this approach also includes a measure of the 
different metabolic adaptations that are likely to occur that support tumor growth 
in actual humans. Finally, by comparing the individualized lung cancer models to 
cell-based experiments one can begin to assess the power and/or limitations of 
conclusions drawn from cell culture experiments. 
 
2.2 Methods 
Cell culture: A549 cells were grown in glucose-free, glutamine-free DMEM 
medium supplemented with 10% FBS, 0.2% glucose, 4 mM glutamine, and 100 
I.U./mL penicillin 100 µg/mLstreptomycin at 37 °C and 5% CO2. Na2SeO3 
(Sigma) solutions were prepared immediately prior to use and sterilized using 
0.22 µm syringe filter. Cells were grown to 70% confluence for all experiments. 
Two hours prior to treatment, medium was aspirated and replaced with half 
volume of the tracer medium containing either 13C6-glucose (Sigma Isotec, St. 
Louis. MO) or 13C5,15N2-Gln (Cambridge Isotopes, Andover, MA). The remaining 
medium was then added with doubled Na2SeO3 concentration in order for cells to 
be conditioned with the tracer medium prior to treatment.  
 
Tissue slices: During NSCLC surgical resection, very thin slices (0.5-1 mm) were 
prepared from tumor and adjacent benign tissue by the operating surgeon (Dr. M. 
Bousamra II). Tissue slices were immediately placed in T-25 culture flasks with 8 
mL DMEM medium supplemented with 10% FBS, 100 I.U./mL penicillin 100 
µg/mLstreptomycin, 0.2% glucose, and 4 mM Gln. Either 13C6-glucose or 
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13C515N2-Gln was used for tracer experiments. Slice medium was then treated 
with or without 6.25 µM Na2SeO3. Flasks were then placed on a rotator in a cell 
culture incubator at 37 °C and 5% CO2 for 24h. After 24h, medium was collected 
for downstream analysis, and tissue slices were washed with PBS before flash 
freezing in LN2.  
 
Proliferation assays: Proliferation of A549 cells was measured in 96-well plates 
according to the protocol by Raspotnig et al. [64]. Briefly, 24 h after treatment 
with selenite, cell medium was aspirated and replaced with 50% ethanol in H2O 
for 30 min. Ethanol was then aspirated and replaced with minimal volume of 
0.2% Janus green dye in PBS for 5 min. Dye was aspirated and plates were 
rinsed in tap H2O and drained by gravity. Dye was then dissolved in 0.5 N HCl 
and absorbance was measured at 595 nm. Growth was reported as the fraction 
of the absorbance for a given concentration of selenite divided by the control 
absorbance. Increasing concentrations of Na2SeO3 were used and the EC50 
concentration was interpolated from the logarithmic transformation of the dose-
response curve. Growth did not reach 0% for the concentrations of Na2SeO3 
used. 
 
Extraction of metabolites: At the time of harvest, medium was collected before all 
plates were washed three times with ice cold PBS, and PBS was removed as 
much as possible by aspiration. The cells’ metabolism was then quenched with 1 
ml of CH3CN kept at -20°C before 0.75 ml of nanopure water was added and 
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cells were harvested by scraping. The process was repeated once before CHCl3 
addition to a final CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, non-
polar and insoluble proteinaceous interface fractions for downstream analysis 
[65, 66]. For metabolite extraction from the medium, protein was first precipitated 
in ice-cold 10% trichloroacetic acid (TCA), and supernatant was lyophilized 
immediately to remove the acid. Since some metabolites such as glutamine are 
sensitive to prolonged storage in acidic conditions, metabolite analysis of 
medium samples by NMR or GC-MS was performed immediately after 
lyophilization. 
 
NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1 
T instrument equipped with 5 mm HCN cold probe. Cell and medium extracts 
were dissolved in D2O with 30 and 50 nmol d6-DSS, respectively, as internal 
standard. Shigemi tubes were used for polar extracts to minimize sample volume 
and thus to concentrate the metabolites. 1D proton spectra were recorded with 
an acquisition time of 2 seconds after initial presaturation of the H2O signal with a 
recycle time of 5 seconds. 1D 13C-filtered HSQC spectra were measured using 
an acquisition time of 150 ms. 1D proton spectra were processed using a 1 Hz 
exponential line broadening function and a zero fill of 128 k points. 1D 13C-filtered 
HSQC spectra were processed with a 6 Hz line-broadening exponential and 0.07 
Hz Gaussian functions and zero filled to 16 k points. Both types of spectra were 
processed manually for baseline and phase corrections. 1D proton spectra were 
referenced using the methyl signal of D6-DSS at 0 ppm, and 1D 13C-filtered 
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HSQC spectra were referenced to the C3-lactate peak at 1.32 ppm and 1.41 ppm 
for cell and medium extracts, respectively. Metabolites were identified in 
reference to an in-house standard database and quantified by calibration with the 
methyl resonance of the DSS internal standard using the MestReNova NMR 
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59]. 
 
GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% N-
tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-
Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS 
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion 
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized 
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary 
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness. 
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60 
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp; 
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan 
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time 
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified 
using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM. 




Nucleotide processing for FT-ICR-MS (Fourier transform-ion cyclotron 
resonance-mass spectrometry) analysis: Nucleotides were ion-paired with 
hexylamine and extracted from polar extracts as described previously [57]. 
Briefly, dried extract aliquots (e.g. 1/16 of one 10 cm plate) were dissolved in 5 
mM hexylamine in H2O (buffer A) with the pH adjusted to 6.3 with acetic acid. 
Dissolved nucleotides were adsorbed onto C18 ZipTips (Millipore, Billerica, MA) 
pre-conditioned with MeOH and buffer A. Bound nucleotides were then washed 
with buffer A followed by elution with 70% buffer A/30% buffer B (90% methanol 
and 10% 10mM ammonium acetate adjusted to pH 8.5 with aqueous ammonia). 
Eluent was then lyophilized and reconstituted in 2:1 MeOH:buffer B for FT-ICR-
MS analysis. 
 
FT-ICR-MS analysis: FT-ICR-MS analysis was performed as described 
previously [57]. Briefly, data were recorded on a hybrid linear ion trap–FT-ICR 
mass spectrometer (Finnigan LTQ FT, Thermo Electron, Bremen, Germany) 
using an automated nanospray ion source (TriVersa NanoMate, Advion 
BioSciences, Ithaca, NY) set with an “A” chip run at 1.5 kV and 0.5 psi head 
pressure. Measurements were recorded for 15 min, which consisted of 14 min of 
high resolution FT-ICR scans, followed by 30 s of low resolution ion trap scans 
(LTQ). FT-ICR-MS scans were recorded from 150-800 Da with a mass resolving 
power set to 400,000 at 400 m/z. At this resolution and mass accuracy the mass 
difference between 12C1,15N1 and 13C1,14N1 is resolved and therefore can be 
independently measured in a double labeling experiment. Each transformed 
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spectrum consisted of 5 summed transients at 2 s per transient for a cycle time of 
10 s. All FT-ICR-MS scans were summed to produce the final spectrum. Spectra 
were then exported via Xcalibur MS software and peaks were corrected and 
assigned using an in-house software (PREMISE  [56]).  
 
Western Blot: At time of harvest cells were lysed directly on the plate using 62.5 
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein 
concentration was measured via the BCA method (Pierce). All protein extracts 
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1 
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and 
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein 
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a 
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then 
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer 
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF 
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room 
temperature in an Invitrogen transfer apparatus All primary antibodies were 
incubated with membrane at 4 °C on a rocker overnight as follows: β-o-linked N--
acetylglucosamine (Sigma, St. Louis, MO), 1:1000 in PBST with 5% BSA; α-
tubulin (epitomics), 1:50,000 in PBST with 5% non-fat powdered milk. 
Membranes were then washed 3 times with PBST before incubating 1 hour at 
room temperature with an HRP-conjugated secondary antibody (Pierce, 1:2000 
in PBST with 5% non-fat powdered milk). Blots were then incubated in Pierce 
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supersignal extended duration chemiluminescent reagent before exposure to x-
ray film (SCBT) for visualization.  
 
GAIMS analysis: GAIMS deconvolution was performed by Dr. Hunter Moseley as 
described previously [55]. FT-ICR-MS measurements from the selenite time 
course of A549 were used to identify UDP-GlcNAc isotopologue intensities. Each 
isotopologue intensity represents combinations of 13C6-glucose, 13C5-ribose, 13C2-
acetyl, and/or 13C1, 13C2, and 13C3-uracil groups in the UDP-GlcNAc molecule. 
Solutions to the equations generated from these combinations are then solved 
via the algorithm. 
 
Statistical analysis: All metabolite amounts were normalized to total protein 
measured via BCA method. All error bars represent the standard deviation of an 
average of experiments (specific number of experiments detailed in appropriate 
figure legends). For statistical significance, the two-tailed Student paired t-test 
was used to calculate p values. Significance was assumed for p values less than 
0.05. For experiments involving multiple measurements (i.e., measurement of 
metabolites from NMR and MS analysis) the false discovery rate method 
described by Benjamini and Hochberg was applied [67].  Briefly, naïve p-values 
for all measured metabolites were calculated. These values were then ranked in 
order of decreasing significance and assigned a rank number. A qi value was 
then calculated according to the equation qi=kpi/i where i=rank of the p value 
among the k tests. The false discovery rate (FDR) was then defined for every qi 
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value such that FDRi=min(qi,…,qk). Tests with p values <0.05 and an FDR value 
<0.05 were then accepted as significant. The following analytes were measured 
and included for statistical analysis via FDR: citrate, fumarate, malate, Asp, 
lactate, glucose, Ser, Ala, UDP-GlcNAc, UTP, ATP, and lactate. 
 
2.3 Results and discussion 
2.3.1 Selenite induces dose-dependent cell death in human lung cancer 
models 
2.3.1.1 Cell culture 
In order to determine an appropriate treatment concentration of Na2SeO3 
for subsequent tracer experiments, the dose-response curve was first 
established in A549 cells, and changes in cell morphology were measured using 
phase contrast microscopy as shown in figure 2.1. The EC50 calculated from the 
curve in figure 2.1A was 6.25 µM for 24 h of treatment. Prominent morphological 
features of A549 cells treated with 6.25 µM Na2SeO3 are illustrated in figure 
2.1B. Features specific to the treated cells included the widespread appearance 
of vacuolar inclusions within the cytoplasm by 6 hours. By 24 hours, these 
vacuoles had diminished in number but were still present. These vacuoles have 
been reported as autophagosomes by Park et al. [22]. Cell detachment was also 
visually more prominent in treated cells than in controls. Also, treated cells were 













Figure 2.1. Selenite effect on A549 proliferation and morphology 
A) A549 cells were treated for 24 h with increasing concentrations of Na2SeO3, and growth was 
measured via Janus green assay. Growth was plotted as the percentage absorbance of 
selenite/CTL. B) A549 cells were treated with or without 6.25 µM Na2SeO3, and images were 























2.3.1.2 Human tissue slices  
Thin (0.5-1 mm) slices of tumor and adjacent benign lung tissue from 
NSLSC surgical patients were also used as an individualized model for human 
lung cancer in parallel with the following cell experiments. These tissue slices are 
analogous to those described by Warburg [29],  but are placed in medium rather 
than on wet blotting paper, thereby giving much greater control over nutrient 
supply and removal of waste products. Such slices represent better models than 
cultured cells as they contain much of the in situ microenvironment that is lost 
with cell cultures. In order first to establish that these tissue slices were 
metabolically viable 24 hours ex vivo, we incubated both cancerous and adjacent 
benign lung tissue with 13C6-glucose  tracer, as described. As indicated by the 
appearance of 13C-1’-AXP satellite peaks at 6.28 and 5.98 ppm in figure 2.2, both 
the cancerous and benign lung tissue slices had synthesized AXP from 13C6-
glucose at the time of harvest. We then treated the slices with 6.25 µM Na2SeO3 
for 24 h as in the cell experiments and afterwards prepared sections for 
histological hematoxylin and eosin (H&E) staining to measure any morphological 
changes. Surprisingly, we found that selenite induced widespread necrosis in the 
tumor tissue that was not observed in the adjacent benign tissue (Fig. 2.3). I thus 
chose to use 6.25 µM Na2SeO3 as the treatment concentration for all subsequent 
tracer experiments based on the dose response of A549 and its efficacy in 






Figure 2.2. Metabolic viability of benign and tumor tissue slices from NSCLC surgical 
patients 
Tissue slices were prepared from resected tumor and adjacent benign lung tissue of NSCLC 
patients and incubated for 24 hours with 13C6-glucose tracer. 13C-1’-AXP satellite peaks (6.28 and 
5.98 ppm) flanking the central 1’-AXP peak at 6.14 ppm indicate incorporation of 13C6-glucose 




















Figure 2.3. Selenite induces necrosis in human lung tissue slices 
Representative hematoxylin and eosin stained histology images from selenite treated tissue 
slices. Tissue slices prepared from resected tumor and adjacent benign lung tissue of NSCLC 









2.3.2 Selenite effects on polar metabolites 
 A549 cells were grown in medium containing 13C6-glucose tracer and 
treated with selenite as described above. Polar metabolites were then extracted 
and measured via 13C-filtered 1D HSQC NMR after harvesting the cells to assess 
selenite-induced perturbations (Fig. 2.4). These spectra indicate protons directly 
attached to 13C atoms and thus represent de novo biosynthesis from labeled 
tracers. Many metabolic pathways were affected by selenite treatment as 
indicated by differences in the amounts of newly synthesized intermediates. As 
shown by the peak at 1.32 ppm, 13C-3-lactate increased in selenite-treated A549 
cells but not in NHBE cells, suggestive of an increase in glycolytic flux or 
increased diversion of pyruvate into lactate at the expense of other metabolites. 
There were also numerous polar metabolites that decreased in the treated cells 
especially 13C-3-Ala, 13C-4-Glu, 13C-4-Glu-glutathione, 13C-2,5-citrate, and 13C-3-
Asp at 1.46, 2.34, 2.54, 2.66, and 2.8 ppm, respectively, indicating decreased 
amino acid synthesis and TCA cycle activity from glucose. In order to determine 
if these selenite-induced changes were cancer cell specific, I then treated 
immortalized NHBE cells with 6.25 µM Na2SeO3 and measured the polar 
metabolites as shown in figure 2.4. Interestingly, the majority of the differences 
observed in A549 were absent or minimal in NHBE suggesting cancer cell 
specificity. 
 I then examined the polar metabolite profile of selenite-treated tumor and 
benign tissue slices as shown in figure 2.4. Many of the metabolic alterations 




Figure 2.4. Selenite effect in 13C6-glucose labeled polar metabolites 
Specified cell lines or tissues were treated with 6.25 µM Na2SeO3 for 24 h with 13C6-glucose 
tracer. Polar metabolites were extracted and measured via 13C-filtered 1D HSQC NMR. Treated 





13C-3-Ala, 13C-4-Glu, 13C-4-Glu-glutathione, 13C-2,5-citrate, and 13C-3-Asp along 
with increased 13C-3-lactate. In contrast, with the exception of lactate, other 
metabolites in the benign tissue showed much smaller effects with selenite 
treatment, analogous to the comparison between A549 and NHBE cells, again 
suggesting cancer specificity. 
 We then repeated the same experiments using 13C5,15N2-Gln in order to 
determine the effect of selenite on metabolites derived from the anapleurotic 
precursor Gln (Fig. 2.5). Again, selenite induced a striking depletion of Krebs’ 
cycle intermediates 13C-2,5-citrate and 13C-3-Asp in selenite-treated A549 cells 
and tumor tissue. Interestingly, 13C-4-Glu decreased while 13C-4-Gln increased, 
in both treated A549 cells and treated cancer tissue. However, there were 
substantially fewer differences between the selenite and control groups in the 
NHBE and benign tissue counterparts. Notably, 13C-4-Glu-glutathione was also 
reduced by selenite treatment. A more detailed investigation of selenite effects 
on glutaminolysis is explored in chapter 3.  
2.3.3 Selenite decreases TCA cycle activity 
 In order to more fully explore selenite-induced TCA cycle disturbances, I 
then measured the time course of enrichment of 13C6-glucose-derived Krebs’ 
cycle isotopologues. By understanding defined reaction mechanisms, one can 
trace the flow of 13C atoms through central metabolic pathways, as illustrated in 
figure 2.6, when a time course design is employed. 13C6-glucose generates 13C2-
acetyl-CoA as it is metabolized through glycolysis and pyruvate dehydrogenase. 
When 13C2-acetyl-CoA condenses with unlabeled oxaloacetate, 13C2-citrate is  
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Figure 2.5. Selenite effect in 13C5,15N2-Gln labeled polar metabolites 
Specified cell lines or tissues were treated with 6.25 µM Na2SeO3 for 24 h with 13C5,15N2-Gln 
tracer. Polar metabolites were extracted and measured via 13C-filtered 1D HSQC NMR. Treated 


























Figure 2.6. 13C flow through glycolysis, PDH, and the TCA cycle 
Filled circles represent 13C atoms. 13C6-glucose is transformed into 13C2-acetyl-CoA, and then 










generated. As shown in figure 2.7A, the depletion of 12C6-citrate was slower in 
selenite treated A549 cells than in controls and had plateaued by 10 hours of 
treatment. Conversely, 13C2-citrate increased more rapidly and to a higher level in 
controls relative to selenite. This implies that glucose is providing less carbon to 
the Krebs’ cycle in the presence of selenite, consistent with the observed 
diversion to lactate shown in figure 2.4. When these same isotopologues were 
measured in immortalized NHBE cells that were treated with selenite for 24 hours 
under the same conditions as A549, the differences between control and selenite 
were not significant (Figs. 2.7C and D). Finally, we measured 13C0 and 13C2-
citrate in tumor and adjacent benign tissue slices from four separate NSCLC 
surgical patients. These tissue slices were cultured in 13C6-glucose, treated with 
or without selenite, and processed similarly to the A549 and NHBE cells. 
Analogous to the cell culture models, we found that 13C2-citrate was significantly 
reduced in the cancer tissue compared to controls (Fig. 2.7E and F). 13C0-citrate 
was not increased to compensate for the selenite-induced reduction in 13C2-
citrate due to an increase in 13C1-citrate. However, no significant differences were 
seen between treatments in the benign tissue.  
13C2-citrate is then transformed into 13C2-α−ketoglutarate, 13C2-succinate, 
and 13C2-fumarate as it is metabolized through the TCA cycle. When 13C0-
fumarate and 13C2-fumarate were measured as above in A549 cells, we observed 
the same isotopologue patterns as in citrate (Figs. 2.8A and B). Fumarate 
enrichment was unaltered by selenite treatment in the treated NHBE group (Figs. 




Figure 2.7. Effect of selenite on 13C6-glucose enrichment of citrate in A549, NHBE, and 
human tissue slices 
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment with 
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells 
were cultured in 13C6-glucose supplemented medium and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in 13C6-glucose supplemented 
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all 
experiments were extracted and citrate was quantified via GC-MS and normalized to total protein. 
*p<0.005; n=4. 
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Figure 2.8. Effect of selenite on 13C6-glucose enrichment of fumarate in A549, NHBE, 
and human tissue slices 
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment 
with or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE 
cells were cultured in 13C6-glucose supplemented medium and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in 13C6-glucose 
supplemented medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar 
metabolites from all experiments were extracted and fumarate was quantified via GC-MS and 
normalized to total protein. *p<0.01; n=4. 	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significantly decreased by selenite treatment specifically in the tumor tissue 
(Figs. 2.8E and F).   
 13C2-fumarate is then converted via fumarase to 13C2-malate, which is also 
measurable via GC-MS. The isotopologue distribution of malate reiterated the 
same pattern described of citrate and fumarate as illustrated in figure 2.9. Finally, 
13C2-malate is converted to 13C2-oxaloacetate via malate dehydrogenase. One 
metabolic fate of 13C2-oxaloacetate is transamination to 13C2-aspartate. I 
measured the aspartate isotopologue distribution as another analogue of TCA 
cycle activity, which reflected the same changes described for citrate, fumarate, 
and malate (Fig. 2.10). Taken together, selenite induced a profound decrease in 
the doubly labeled Krebs’ cycle intermediates citrate, fumarate, malate, and 
aspartate in A549 lung cancer cells. These changes were specific to A549 
relative to immortalized NHBE cells. Interestingly, 13C2-malate appeared to be 
slightly increased with selenite treatment in NHBE. These findings were then 
recapitulated in the individualized lung cancer tissue slice model indicating a 
cancer specific decrease in the flux through the TCA cycle caused by selenite.  
2.3.4 Selenite stimulates glycolysis in A549 
 One immediately obvious feature from the selenite-treated A549 spectra in 
figure 2.4 was increased 13C-3-lactate. 13C3-pyruvate generated via glycolysis of 
13C6-glucose can in turn generate 13C3-lactate through lactate dehydrogenase. 
This process restores oxidizing equivalents for substrate level phosphorylation by 
replenishing NAD+ and is a hallmark of tumor metabolism [29]. However, 




Figure 2.9. Effect of selenite on 13C6-glucose enrichment of malate in A549, NHBE, and 
human tissue slices 
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment with 
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells 
were cultured in 13C6-glucose supplemented medium and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in 13C6-glucose supplemented 
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all 












Figure 2.10. Effect of selenite on 13C6-glucose enrichment of Asp in A549, NHBE, and 
human tissue slices 
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment with 
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. C and D) NHBE cells 
were cultured in 13C6-glucose supplemented medium and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. E and F) Patient tissue slices were cultured in 13C6-glucose supplemented 
medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all 
experiments were extracted and malate was quantified via GC-MS and normalized to total 




a small fraction of the total lactate produced as most of the lactate generated 
from anaerobic fermentation is exported from the cell. Therefore, I also measured 
extracellular lactate production by quantifying the time course lactate 
isotopologue distribution in the media of 13C6-glucose labeled A549 as shown in 
figure 2.11. The medium measurements reiterated the cellular measurements 
and showed a substantial increase in 13C3-lactate production in selenite-treated 
media suggestive of increased utilization of glucose for lactate at the expense of 
acetyl-CoA (Fig. 2.11B). In order to determine whether or not increased lactate 
synthesis is indicative of an increase in flux through glycolysis, one must 
consider the rate of glucose consumption as shown in figure 2.12. Linear 
regression analysis of lactate production and glucose consumption indicated ~4 
and ~2-fold increases, respectively, in selenite-treated cells (Table 2.1). These 
values are consistent with a selenite-induced increase in glycolytic flux along with 
reallocation of glucose carbon for lactate synthesis at the expense of TCA cycle 
intermediates as further illustrated in figure 2.13.  
Selenite-induced stimulation of lactic fermentation is likely compensating 
for reduced TCA cycle activity evidenced by the attenuated 13C2 intermediates 
discussed above. Interestingly, selenite-treated A549 media also accumulated 
13C2-lactate. A variety of labeling patterns of lactate can be generated through 
two rounds of the TCA cycle and malic enzyme catalyzed conversion of malate to 
pyruvate followed by lactate production via lactate dehydrogenase as depicted in 
figure 2.14. If pyruvate is generated from doubly labeled malate via malic 

















Figure 2.11. Effect of selenite on lactate production in A549 
A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment with or without 
6.25 µM Na2SeO3. Harvest hour denotes time after treatment. 13C2 (A) and 13C3 (B)-lactate 
isotopologues were quantified via GC-MS from medium aliquots taken from the onset of 
treatment (0 h) and at cell harvest. 0 h values were subtracted from harvest hour values and the 


















Figure 2.12. Effect of selenite on glucose consumption in A549 
13C6-glucose was quantified from 1D proton NMR spectra generated from medium aliquots taken 
at the onset of treatment (0h) and at cell harvest. Cells were pre-incubated with 13C6-glucose 
tracer for 2 hours before treatment with 6.25 µM Na2SeO3. 0h values were subtracted from 





























Table 2.1 Linear regression analysis of lactate production and glucose consumption in 
selenite-treated A549 cells 
Linear regression was applied to data from figures 2.11 and 2.12, and the above variables were 
calculated. Slopes of selenite-treated cells were significantly different from non-treated controls 






Figure 2.13. Effect of selenite glucose carbon allocation to lactate 
13C6-glucose and 13C3-lactate were quantified from 1D proton NMR spectra generated from 
medium aliquots taken at the onset of treatment (0h) and at cell harvest. Cells were pre-incubated 
with 13C6-glucose tracer for 2 hours before treatment with 6.25 µM Na2SeO3. 0h values were 
subtracted from harvest hour values for glucose, and lactate was divided by glucose consumed to 









Figure 2.14. 13C flow through glycolysis, TCA cycle, malic enzyme, and lactate 
dehydrogenase 
As 13C6-glucose is metabolized through glycolysis and the TCA cycle eventually symmetric 13C2-
fumarate is generated, which generates two distinct 13C2 isotopomers of malate. If 13C2-malate is 
decarboxylated via malic enzyme to pyruvate, 13C2 and 13C1-pyruvate should be created in equal 
amounts. If doubly labeled malate continues through another round of the TCA cycle with doubly 
labeled acetyl-CoA, then 13C2 and 13C3 pyruvate will be generated a ratio of 3:1. Generation of 
lactate from labeled pyruvate will create the isotopomer distribution displayed above. Blue filled 






































very little 13C1 was measured in the media. If doubly labeled malate undergoes 
another round of TCA cycle conversions with doubly labeled acetyl-CoA, then a 
predominance of 13C2-lactate will eventually be generated. Therefore, when the 
possibilities of lactate generation from glycolysis and malic enzyme (ME) are 
taken into consideration, a predominance of 13C2 and 13C3-lactate will be formed. 
However, it is puzzling that 13C2-lactate would accumulate in selenite-treated 
cells, since TCA cycle activity is reduced and lactate production from Gln 
appears to be negligible. However, if malic enzyme activity is increased upon 
selenite treatment, doubly labeled Krebs’ cycle intermediates could be siphoned 
off for lactic fermentation ultimately reducing the amounts of measurable 13C2 
intermediates. Notably, ME was indeed increased by selenite treatment at the 
mRNA level as reported by Fan et al. [60]. 
 As another measure of glucose utilization, we measured the serine 
isotopologue distribution in selenite-treated A549 and NHBE cells. 13C6-glucose 
is eventually converted through glycolysis to 13C3-3-phosphoglycerate, which is a 
biosynthetic precursor for serine.13C3-Ser enrichment in treated A549 cells was 
increased relative to controls; however, no differences were noted in treated 
NHBE cells, which is again consistent with an increase allocation of glucose 
carbon to lactate (Fig 2.15). These patterns indicate selenite induces a cancer-
specific increase in glycolysis, which is likely a compensatory mechanism for 
decreased flux through the TCA cycle. 
Finally, I measured both the cellular and extracellular alanine isotopologue 




Figure 2.15. Effect of selenite on 13C6-glucose derived enrichment of serine in A549 and 
NHBE 
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose and treated with or without 
6.25 µM Na2SeO3. C and D) NHBE cells were cultured in 13C6-glucose supplemented medium 
and treated with or without 6.25 µM Na2SeO3 for 24 hours. Polar metabolites from all experiments 









pyruvate through alanine transaminase, and an isotopologue distribution similar 
to lactate is possible as shown in figure 2.14. Examination of the medium alanine 
production indicated increased production of 13C3-Ala in controls and increased 
production of 13C2-Ala in the treated A549 medium (Figs. 2.16A and B). 
Quantification of cellular Ala reiterated these findings (Figs. 2.16C and D). 
Selenite-increased 13C2-Ala may arise from increased 13C2-lactate as discussed 
previously. But in this scenario, 13C3-Ala was actually decreased in the selenite 
group relative to controls. The data are puzzling; however, one possible solution 
for this distribution would be a combination of increased malic enzyme and 
lactate dehydrogenase activity. Increased flux through malic enzyme could 
generate 13C2 and 13C3-pyruvate in selenite treated cells. If lactate 
dehydrogenase activity were increased in order to replenish NAD+, then most of 
the pyruvate would be siphoned off for lactate synthesis. Some of the doubly and 
triply labeled pyruvate could generate correspondingly labeled alanine, which is 
illustrated by the measured increase in 13C2-Ala. However, since the controls are 
generating predominantly 13C3-Ala, the overall 13C3-Ala enrichment is actually 
greater than with selenite treatment. Taken together these data strongly indicate 
that selenite increases glycolytic activity.  
2.3.5 Selenite decreases nucleotide synthesis 
 In an ongoing effort to characterize selenite-induced metabolic 
perturbations, I then examined nucleotide synthesis. Analysis of the 1D proton 
spectra from a set of unlabeled selenite experiments indicated that several of the 








Figure 2.16. Effect of selenite on 13C6-glucose derived enrichment of Ala in A549  
A and B) A549 cells were pre-incubated for 2 hours with 13C6-glucose followed by treatment with 
or without 6.25 µM Na2SeO3. Harvest hour denotes time after treatment. 13C2 (A) and 13C3 (B)-Ala 
isotopologues were quantified via GC-MS from medium aliquots taken from the onset of 
treatment (0 h) and at cell harvest. 0 h values were subtracted from harvest hour values and the 
resulting quantity was normalized to total protein to calculate the amount of Ala produced. C and 
D) Intracellular Ala measurements from the same experiment. Polar metabolites were extracted 










including UDP-GlcNAc (Fig. 2.17A). Selenite-induced reduction of these same 
nucleotide hexoses was substantially less when the experiment was repeated in 
NHBE cells (Fig. 2.17A). Quantitation yielded a ~2-fold decrease in selenite-
treated A549 cells and a somewhat smaller decrease in NHBE cells (Fig. 2.17B 
and C). Interestingly, UDP-GlcNAc was more substantially affected by selenite 
treatment than UDP-GalNAc in both A549 and NHBE, suggesting some 
specificity for UDP-GlcNAc synthesis. I then measured the time course of 
enrichment of UDP-GlcNAc, UTP, and ATP in selenite-treated A549 cells using 
both 13C6-glucose and 13C5,15N2-Gln tracers. UDP-GlcNAc is both analytically and 
biologically interesting as its synthesis involves contributions from glycolysis, 
pentose phosphate pathway, hexosamine biosynthetic pathway, Krebs’ cycle, 
nucleotide biosynthesis, and glutaminolysis (Figs. 2.18A and B). By analyzing the 
time course enrichment of UDP-GlcNAc from labeled precursors, one can make 
conclusions about the flux through the pathways that contribute towards its 
synthesis. When we measured UDP-GlcNAc isotopologues from selenite-treated 
A549 cells with 13C6-glucose tracer, I found that the time course of enrichment 
was generally attenuated with respect to controls (Fig. 2.19). 13C5, 13C6, and 
13C13-UDP-GlcNAc enrichment was delayed in selenite-treated cells as shown in 
figures 2.19B, C, and D. Furthermore, the enrichment of more fully labeled 
isotopologues such as 13C15-UDP-GlcNAc was immeasurable in selenite treated 
A549 cells (Fig. 2.19E).  
    Presumably, 13C5 and 13C6-UDP-GlcNAc represent isotopologues having fully 














Figure 2.17. Effect of selenite on nucleotide hexosamines 
A) A549 and NHBE cells were treated with or without 6.25 µM Na2SeO3 for 24h. Polar 
metabolites were extracted, and 1D proton spectra were recorded. Spectra were superimposed 
and normalized to total protein to assess differences. UDP-GlcNAc peaks at 5.5 ppm were 
quantified in A549 (B) and NHBE (C) using Mnova spectral analysis software and normalized to 





















Figure 2.18. Contributions from glucose and Gln in UDP-GlcNAc biosynthesis 
A) Heavy carbon from 13C6-glucose is incorporated into UDP-GlcNAc at several points during its 
synthesis. 13C2 or 13C3-Asp generated from the flow of 13C through glycolysis, PDH, Krebs’ cycle, 
and transamination of labeled OAA is incorporated into the uracil ring. 13C5-ribose of the 
nucleoside diphosphate is generated from glycolysis the pentose phosphate pathway. The 13C6-
glucose moiety of UDP-GlcNAc is generated during the first few steps of the HBP. Finally, the 
13C2-acetyl group is generated from glycolysis and PDH. B) 13 C and 15N from 13C5,15N2-Gln are 
incorporated into UDP-GlcNAc at several points during its synthesis. CPS II can generate labeled 
15N3 uracil from 13C5,15N2-Gln substrate. Uracil 15N1 is generated from transamination of either 
fully labeled or unlabeled OAA with 13C5,15N2-Gln. 13C4-6 of uracil can be generated through 
glutaminolysis of 13C5,15N2-Gln and subsequent transformation of fully labeled Glu and a-KG 
through the TCA cycle to 13C4-OAA, which can then be transaminated from 13C5,15N2-Gln to form 
fully labeled Asp. 13C4,15N1-Asp is then incorporated into the uracil ring during pyrimidine 
synthesis. The amino group of glucosamine can be generated from the GFAT reaction of the HBP 
using 13C5,15N2-Gln as substrate. Finally, the acetyl group of N-acetylglucosamine can be 
generated from 13C4-malate followed by malic enzyme mediated conversion to 13C-pyruvate and 











Figure 2.19. Effect of selenite on UDP-GlcNAc enrichment from glucose 
FT-MS quantified 13C0 (A), 13C5 (B), 13C6 (C), 13C13 (D), and 13C15 (E) UDP-GlcNAc isotopologues. 
A549 cells were pre-incubated with 13C6-glucose for 2 hours and then treated with or without 6.25 
µM Na2SeO3. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment. Nucleotides 
were extracted and UDP-GlcNAc was measured via FT-MS. Plots represent the intensity of the 




and depletion as more fully labeled species are generated. 13C13- and 13C15-UDP-
GlcNAc likely represent ribose plus glucose labeling and combinations of labeling 
in the acetyl group and uracil ring. Taken together these enrichment patterns 
indicate delayed enrichment of ribose and glucose with preferential blockage of 
the uracil and/or acetyl subunits.  
 In order to more fully explore these enrichment patterns, the FT-MS data 
were deconvoluted using the genetic algorithm for isotopologues in metabolic 
systems or “GAIMS” developed by Dr. Hunter Moseley. This non-steady-state 
modeling algorithm deconvolutes the UDP-GlcNAc isotopologue data into the 
time course enrichment of its subunits: glucose, ribose, uracil, and the acetyl 
group. When the algorithm was applied, the results indicated that the acetyl 
group and uracil enrichment were preferentially delayed by selenite treatment as 
illustrated in figures 2.20C, D, and E. However, ribose and glucose enrichment 
were less substantially affected by selenite treatment, despite the increased 
uptake rate of glucose (Figs. 2.20A and B). These findings are again consistent 
with an increase in glycolytic flux and reallocation of glucose carbon into lactate 
at the expense of pyrimidine synthesis as well as ribose synthesis via the PPP. 
Interestingly, the flux of glucose carbon through the HBP appears to be mostly 
intact with selenite treatment and preferentially blocked downstream of 
glucosamine synthesis as suggested by the negligible effect on 13C6-UDP-
GlcNAc accumulation. 
 When we examined the enrichment patterns in NHBE cells incubated with 




















Figure 2.20. GAIMS deconvolution of UDP-GlcNAc isotopologue distribution in A549   
FT-MS data from figure 2.18 were deconvoluted as described. Individual plots represent the time 
course enrichment of the 13C6-glucose (A), 13C5-ribose (B), 13C2-acetyl (C), and 13C1-3-uracil (D-F) 
subunits of UDP-GlcNAc. Data are represented as the fraction of selenite treated subunit over the 




enrichment (Figs. 2.21A-D). We then measured the UDP-GlcNAc isotopologue 
distribution generated from tumor and adjacent benign tissue slices treated with 
selenite and incubated with 13C6-glucose tracer for 24 hours. Enrichment of the 
acetyl group and/or uracil ring appeared to be preferentially blocked in both the 
tumor and benign tissue as evidenced by decreased amounts of 13C13-UDP-
GlcNAc.   
I then measured the UDP-GlcNAc isotopologue distribution generated 
when A549 cells were incubated with 13C5,15N2-Gln tracer. As expected, 
13C0,15N0-UDP-GlcNAc plateaued at a higher level in selenite-treated cells than in 
controls (Fig. 2.22A). In order to assess the rate of depletion in treated cells, the 
data were assumed to follow the simple exponential decay model: 
 !! =  < ! > +  (!!−  < ! >)!!"                       Eq. 2.1 
As illustrated in table 2.2 the rate of 13C0,15N0-UDP-GlcNAc depletion in selenite-
treated cells was actually greater than in controls suggesting a possible 
stimulation of UDP-GlcNAc synthesis or utilization initially, followed by an abrupt 
decrease as nitrogen and carbon from Gln are blocked from entry into these 
pathways. 
Interestingly, 13C0,15N1-UDP-GlcNAc accumulated in selenite treated cells 
in contrast to controls, suggesting that at least one nitrogen-donating step in 
UDP-GlcNAc synthesis was not inhibited by treatment (Fig. 2.22B). 13C2,15N1-
UDP-GlcNAc also accumulated with selenite treatment as shown in figure 2.22C, 








Figure 2.21. Effect of selenite on UDP-GlcNAc enrichment from glucose in NHBE and 
human tissue slices 
NHBE cells were incubated with 13C6-glucose and treated with or without 6.25 µM Na2SeO3 for 24 
hours. Nucleotides were extracted and 13C5 (A), 13C6 (B), 13C13 (C), and 13C15 (D) UDP-GlcNAc 
isotopologues were measured via FT-MS. Plots represent the intensity of the designated 
isotopologue divided by the total intensity as a percentage. E) Patient tissue slices were cultured 
in 13C6-glucose supplemented medium and treated with or without 6.25 µM Na2SeO3 for 24 hours. 
Nucleotides were extracted and UDP-GlcNAc isotopologue fractional distribution was measured 
via FT-MS. The fractional enrichment of selenite-treated isotopologue was then divided by the 
corresponding non-treated control value for each sample to obtain the fraction of control for each 













Figure 2.22. Effect of selenite on UDP-GlcNAc enrichment from Gln in A549 
A549 cells were pre-incubated for 2 hours with 13C5,15N2-Gln and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment. 
Nucleotides were extracted and UDP-GlcNAc was measured via FT-MS. Plots represent the 




Table 2.2. Effect of selenite on exponential decay of 13C0,15N0-UDP-GlcNAc in A549 
13C0,15N0-UDP-GlcNAc FT-MS data were fit to the equation, yt= <y> + (y0 - <y>)-kt, in order to 







and then acetyl-CoA was functioning as described earlier. However, this result is 
puzzling given that flux through glutaminolysis and subsequently the TCA cycle is 
clearly impeded with selenite treatment. Perhaps there is an initial brief 
stimulation of glutaminolysis as suggested by table 2.2 followed by inhibition 
which results in accumulation of 13C2,15N1-UDP-GlcNAc as more fully labeled 
isotopologues are blocked. More highly labeled isotopologues, including 
13C3,15N2, 13C2,15N3, 13C3,15N3, and 13C5,15N3-UDP-GlcNAc, were greatly 
attenuated by selenite, reinforcing that two out of the three nitrogen donating 
steps were inhibited along with incorporation of fully labeled Asp from labeled 
OAA transamination (Figs. 2.22D-F).  
 Surprisingly, when I measured UDP-GlcNAc isotopologues in NHBE cells 
grown with 13C5,15N2-Gln tracer nearly 100% were unlabeled, indicating little if 
any de novo synthesis from Gln. Furthermore, there was no effect from selenite 
on the distribution (Fig. 2.23A and B). As indicated in figure 2.17, UDP-GlcNAc 
represents a substantial portion of the hexosamine nucleotide pool. Taken 
together, these data suggest that de novo synthesis of UDP-GlcNAc in NHBE 
cells incorporates carbon and nitrogen primarily from glucose and/or endogenous 
Gln to maintain steady concentrations upon cell division. I then repeated these 
measurements in the tissue slice model with 13C5,15N2-Gln tracer from three 
different patients. I found that selenite significantly reduced 13C0,15N1, 13C0,15N2, 
and 13C0,15N3-UDP-GlcNAc in tumor tissue compared with paired benign lung 
tissue suggesting inhibition of the nitrogen donating steps in hexosamine 



















Figure 2.23. Effect of selenite on UDP-GlcNAc enrichment from Gln human patient tissue 
slices 
A and B) NHBE cells were incubated with 13C5,15N2-Gln and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. Nucleotides were extracted and UDP-GlcNAc was measured via FT-MS. 
Plots represent the intensity of the designated isotopologue divided by the total intensity as a 
percentage. C) UDP-GlcNAc isotopologue distribution from selenite-treated tumor and adjacent 
benign tissue slices. Data represent the average from three separate patients depicted as fraction 





In order to discriminate labeling differences in UDP-GlcNAc between uracil 
and the acetyl group caused by selenite, I then measured enrichment patterns in 
UTP. UTP contains the uracil ring and ribose of UDP-GlcNAc without N-
acetylglucosamine. Therefore, by studying tracer incorporation into UTP one can 
make assumptions about which specific steps of UDP-GlcNAc synthesis were 
inhibited by selenite treatment. When A549 cells were given 13C6-glucose tracer, 
unlabeled UTP plateaued at a higher level with selenite treatment, again 
suggesting either decreased synthesis or utilization of UTP (Fig. 2.24A). 
Analogous to table 2.2, the rate of 13C0-UTP was modeled using equation 2.1 
(Table 2.3). 13C0-UTP decreased at the same rate for both controls and selenite-
treated cells, suggesting that selenite reduced the overall synthesis from glucose 
and/or utilization of UTP, but not the initial rate. Selenite delayed 13C5-UTP 
accumulation; however, 13C7-UTP was substantially more affected suggesting 
preferential inhibition in Asp label incorporation (Figs. 2.24B and C). When the 
experiment was repeated using 13C5,15N2-Gln tracer, similar pathways appeared 
to be affected. Specifically, labeled Asp incorporation into the uracil ring was 
preferentially blocked by selenite treatment as evidenced by the depletion of 
13C3,15N1 and 13C3,15N2-UTP (Figs. 2.24F and G). The predominant isotopologue 
observed in the selenite-treated cells was fully unlabeled UTP (Fig. 2.24D), and 
all others were either absent or depleted for the duration of the experiment, 
suggesting that transamination of fructose-6-phosphate to glucosamine-6-
phosphate during hexosamine biosynthesis is not as affected by selenite 






















Figure 2.24. Effect of selenite on UTP enrichment from glucose and Gln in A549 
A-C) A549 cells were pre-incubated for 2 hours with 13C6-glucose and treated with or without 6.25 
µM Na2SeO3 for 24 hours. D-G) A549 cells were pre-incubated for 2 hours with 13C5,15N2-Gln and 
treated with or without 6.25 µM Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, 
and 24 hours post treatment. Nucleotides were extracted and UTP was measured via FT-MS. 




Table 2.3. Effect of selenite on exponential decay of 13C0-UTP in A549 
13C0-UTP FT-MS data were fit to the equation, yt= <y> + (y0 - <y>)-kt, in order to obtain the above 








isotopologues from both tracers in treated NHBE cells, no differences between 
treatments were noted. Again, I observed very little incorporation of Gln label 
(Fig. 2.25). Interestingly, the treated tissue slices recapitulated the selenite 
effects on tumor tissue, specifically with regards to Asp incorporation into the 
uracil ring (Fig. 2.26). 
Finally, I measured the isotopologue distributions in ATP as a 
representation of purine metabolism using the experiments detailed above (Fig 
2.27). Similar to UDP-GlcNAc and UTP, unlabeled ATP plateaued at a higher 
level in selenite-treated A549 cells as shown in figure 2.27A, suggesting 
decreased synthesis or utilization. The rates of both 13C0-ATP depletion and 13C5-
ATP accumulation were modeled using equation 2.1 and the following model: 
 ! = !!+< ! > (1− !!!")                                 Eq. 2.2 
As shown in table 2.4, the depletion rate of unlabeled ATP was the same for both 
treated and untreated A549; however, the rate of 13C5-ATP was significantly 
reduced in selenite-treated cells. These data are consistent with an overall 
decrease in the synthesis from glucose and/or utilization of ATP with selenite 
treatment.  
 Consistent with the parameters determined in table 2.4, labeling of the 
ribose subunit was slightly delayed, while enrichment of the adenine ring was 
significantly slower as evidenced by figures 2.27B and C. Carbon in the adenine 




Figure 2.25. Effect of selenite on UTP enrichment from glucose and Gln in NHBE 
NHBE cells were incubated with either 13C6-glucose (A-C) or 13C5,15N2-Gln (D and E) and treated 
with or without 6.25 µM Na2SeO3 for 24 hours. Nucleotides were extracted and UTP was 
measured via FT-MS. Plots represent the intensity of the designated isotopologue divided by the 







Figure 2.26. Effect of selenite on UTP enrichment from glucose and Gln in human patient 
tissue slices 
Tumor and adjacent benign tissue slices were incubated with 13C6-glucose (A) or 13C5,15N2-Gln 
(B) tracers and treated with or without 6.25 µM Na2SeO3 for 24 h. Nucleotides were extracted and 
UTP was measured via FT-MS. Data represent the average from three separate patients 





Figure 2.27. Effect of selenite on ATP enrichment from glucose and gln in A549 
A-C) A549 cells were pre-incubated for 2 hours with 13C6-glucose and treated with or without 6.25 
µM Na2SeO3 for 24 hours. D-H) A549 cells were pre-incubated for 2 hours with 13C5,15N2-Gln and 
treated with or without 6.25 µM Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, 
and 24 hours post treatment. Nucleotides were extracted and ATP was measured via FT-MS 











Table 2.4. Effect of selenite on exponential decay of 13C0-ATP and accumulation of13C5-ATP 
in A549 
13C0 and 13C5-ATP FT-MS data were fit to the equations, yt= <y> + (y0 - <y>)-kt and y = y0 + <y>(1 
– e-kt), respectively, in order to obtain the above variables. K values for the rate of 13C0-ATP 
depletion were statistically the same, but were significantly different for 13C5-ATP accumulation 
















appeared to accumulate before 13C2-Gly in A549 control cells incubated with 
13C6-glucose tracer, and enrichment was delayed by selenite treatment; however, 
the validity of these data were compromised due to noise (Fig. 2.28). Since the 
entire Gly backbone is incorporated into the adenine ring, one would expect to 
find 13C1 followed by 13C2 labeling in the adenine ring based upon the Gly 
enrichment pattern. This is likely why 13C1-adenine accumulates in A549 cells, 
since 13C6-ATP is presumably 13C5-ribose plus 13C1-adenine as 13Cribose-ATP is 
clearly and independently measurable from the NMR spectra shown in figure 2.4. 
However, 13C could also be contributed from N10-formyl-THF, which can itself be 
synthesized in part from Gly or Ser, so it is difficult to determine precisely where 
the adenine label is derived from. 
Four out of the five nitrogen atoms in ATP can be traced back to Gln as 
their source, either directly or from Asp transamination as supported by a 
predominance of 13C0,15N4-ATP seen in the 13C5,15N2-Gln labeled controls of 
figure 2.27H. The predominant isotopologue observed for selenite-treated cells 
from this experiment was unlabeled ATP, again suggesting decreased purine 
synthesis and/or utilization (Fig. 2.27D). Interestingly, 13C0,15N1-ATP also 
accumulated in selenite treated A549 cells; however, due to the similarity of 
nitrogen donating steps during purine synthesis, it is likely a combination of 15N1-
adenine isotopomers (Fig. 27E). Analysis of the isotopologue distribution in 13C6-
glucose and 13C5,15N2-Gln labeled NHBE cells again yielded little if any changes 
induced by selenite treatment (Fig. 2.29). Interestingly, ATP also incorporated 















Figure 2.28. Effect of selenite on Gly enrichment from glucose in A549 
A549 cells were pre-incubated for 2 hours with 13C6-glucose and treated with or without 6.25 µM 
Na2SeO3 for 24 hours. Cells were harvested at 0, 1.5, 3, 6, 10, and 24 hours post treatment. Polar 
metabolites were extracted and Gly was measured via GC-MS and normalized to total protein. 












Figure 2.29. Effect of selenite on ATP enrichment from glucose and Gln in NHBE 
NHBE cells were incubated with either 13C6-glucose (A-C) or 13C5,15N2-Gln (D) and treated with or 
without 6.25 µM Na2SeO3 for 24 hours. Nucleotides were extracted and ATP was measured via 
FT-MS. Plots represent the intensity of the designated isotopologue divided by the total intensity 




























Fig. 2.30. Effect of selenite on ATP enrichment from glucose and Gln in human patient 
tissue slices 
Tumor and adjacent benign tissue slices were incubated with 13C6-glucose (A) or 13C5,15N2-Gln 
(B) tracers and treated with or without 6.25 µM Na2SeO3 for 24 h. Nucleotides were extracted and 
ATP was measured via FT-MS. Data represent the average from three separate patients depicted 





predominance of unlabeled ATP with 13C5,15N2-Gln tracers (Fig. 2.29D). Finally, 
when we applied fully labeled glucose tracer to the tissue slices, we found that 
selenite had little effect on enrichment of ribose (Fig. 2.30A). Nitrogen 
incorporation from 13C5,15N2-Gln tracer into the adenine ring of ATP was 
significantly reduced with selenite treatment in the cancer tissues; however, 
benign tissues were also significantly affected as illustrated in figure 2.30B, and 
actually more so for 13C0,15N2-ATP.  
2.3.6 Selenite decreases UDP-GlcNAc utilization 
 As discussed previously, UDP-GlcNAc decreased in selenite treated A549 
cells substantially more so than in NHBE cells (Fig. 2.17). In order to determine if 
this decrease in UDP-GlcNAc was matched by a decrease in its utilization for 
protein modification, I examined the levels of O-GlcNAc glycosylation in selenite 
treated A549 cells. Interestingly, selenite induced a global reduction in O-GlcNAc 
modification as shown in figure 2.31. Glycosylation was also measured in NHBE 
cells and was less than in untreated A549 cells, analogous to the difference 
between tumor and benign tissue reported in the literature [45]. Furthermore, 
selenite did not have any effect on O-GlcNAc glycosylation in NHBE. I then 
attempted to isolate several putative targets of O-GlcNAc modification including 
the proto-oncogene protein c-MYC and mitochondrial transporter VDAC, both of 
which have been established as targets of OGT. Selenite has a significant effect 
on glutaminolysis and TCA cycle activity (see above); therefore, I chose to focus 
on c-MYC and VDAC due to their roles in Gln and mitochondrial metabolism, 















Figure 2.31. Effect of selenite on UDP-GlcNAc utliization 
A549 cells were treated with or without 6.25 µM Na2SeO3 for 24 hours and total protein was 
extracted. Lysates from treated A549 and untreated NHBE cells were probed for o-GlcNAc 










appeared to be modified by UDP-GlcNAc. We have since begun to focus on a 




 By utilizing tracer-based experimental design, this study was able to 
expand upon previous work by Fan et al. [60] on selenite-induced disruption of 
cancer cell metabolism. NSCLC tissue slices were demonstrated to be 
metabolically viable due to their uptake and incorporation of labeled tracers into 
metabolic intermediates. Furthermore, selenite induced massive necrosis in 
cancer tissue that was unmatched in the adjacent benign tissue, thereby 
illustrating its potency as an anti-cancer agent for this model. In order to expand 
upon these findings, I then pursued a thorough metabolic profile of selenite-
perturbed metabolism by contrasting A549 human lung cancer cells with 
immortalized NHBE cells and NSCLC lung tissue.  
 During this investigation, I studied numerous selenite-induced 
disturbances in A549 metabolism. The driving force behind many of these effects 
seems to be a dramatic attenuation of glutaminolysis induced by selenite. Gln is 
one of the major anapleurotic substrates of the TCA cycle, and it contributes both 
carbon and nitrogen for the biosynthesis of amino acids, nucleotides, and Krebs’ 
cycle intermediates to facilitate aerobic respiration. When A549 cells were 
labeled with 13C6-glucose, I found a dramatic reduction in the enrichment of 
doubly labeled TCA cycle intermediates citrate, fumarate, and malate along with 
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doubly labeled Asp suggestive of decreased entry of glucose into the cycle. 
Furthermore, when 13C5,15N2-Gln tracer was applied, I found a severe depletion 
and accumulation of labeled Glu and Gln, indicating impaired glutaminolysis. 
Together, this indicates a  decrease in flux through the TCA cycle that would 
presumably lead to an impaired ability to generate NADH and FADH2 for 
oxidative phosphorylation, as well as provide intermediates for anabolic 
metabolism. As evidenced by the increase in 13C3-lacate and 13C3-Ser with 
selenite treatment, glycolytic flux is likely accelerated in order to augment the 
high cancer cell energy requirements through substrate level phosphorylation. 
Interestingly, I found that this effect on TCA flux was not reproduced in NHBE 
cells, suggesting that these effects are somehow cancer specific. Furthermore, 
selenite-induced Krebs’ cycle flux attenuation was recapitulated in the tissue slice 
experiments, reinforcing this hypothesis within the actual tumor 
microenvironment. 
 I then examined labeling patterns in UDP-GlcNAc, UTP, and ATP from 
13C6-glucose and 13C5,15N2-Gln to determine if these disturbances in TCA cycle 
flux and anapleurosis were propagated into nucleotide synthesis. Through the 
analysis of 13C6-glucose labeled UDP-GlcNAc and subsequent GAIMS 
deconvolution, I showed that uracil and acetyl group enrichment were 
preferentially delayed by selenite treatment. Uracil synthesis requires 
incorporation of Asp into its ring, which itself is a product of Krebs’ cycle 
intermediate OAA’s transamination. Given that selenite reduces anapleurosis of 
the TCA cycle, it follows that Asp synthesis would also be reduced as well as its 
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incorporation into the uracil ring. In addition, uracil biosynthesis requires the 
activity of the mitochondrial enzyme dihydroorotate dehydrogenase, which 
requires reoxidation of the flavin by ubiquinone (cf complex II) and thus a 
functional respiratory chain [71].  Furthermore, selenite-induced stimulation of 
glycolysis and subsequent lactic acid fermentation to replenish NAD+ could 
reduce flux through pyruvate dehydrogenase, limiting the acetyl-CoA substrate 
available for acetylation of glucosamine-6-phosphate during the glucosamine-6-
phosphate N-acetyltransferase reaction. These blocked steps in hexosamine 
synthesis resulted in a significant reduction of total UDP-GlcNAc in A549 cells.  
 Examination of 13C5,15N2-Gln incorporation into UDP-GlcNAc and UTP 
reiterated these findings, illustrating that uracil synthesis from Asp was impaired 
by selenite. GFAT catalyzed transamination of fructose-6-phosphate to 
glucosamine-6-phosphate appeared to be the only nitrogen-donating reaction of 
UDP-GlcNAc synthesis that was not inhibited by selenite treatment, likely due to 
the increased pool of Gln available due to diminished glutaminolysis. When I 
repeated the experiments in NHBE cells, I found no effect from selenite on 
nucleotide synthesis. Furthermore, NHBE cells did not utilize exogenous Gln for 
nucleotide synthesis, reinforcing that Gln is a preferential nutrient of transformed 
cancer cells. Here again, analysis of tissue slice nucleotide synthesis from 
labeled precursors recapitulated the findings from the cell-based experiments 
illustrating a selenite-induced reduction in biosynthesis. Benign tissues were, 
however, affected as well by selenite treatment suggesting some effect on 
nucleotide synthesis in the surrounding lung tissue. Differences in the response 
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to selenite between tumor and adjacent benign tissue are likely to be smaller 
than in cell monoculture. The presence of stromal cells, in both the tumor and 
benign tissue along with inflammation, is partially responsible for reducing these 
differences.  
 Finally, I found that the reduction in UDP-GlcNAc biosynthesis caused by 
selenite was followed by a global reduction in its glycosylation of protein targets 
by OGT. Given the increasing recognition of the importance of O-GlcNAcylation 
in protein regulation[49-51], these selenite-induced downstream effects could 
have compounding implications for tumor cell survival and proliferation. However, 
further work is needed in order to determine which potential targets may be 
mediating these effects. 
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CHAPTER 3-SELENITE INHIBITS GLUTAMINOLYSIS BY 
DECREASING THE EXPRESSION OF GAC 
3.1 Introduction 
 Selenium is a micronutrient that is incorporated into the 21st protein coding 
amino acid, selenocysteine [10]. It functions primarily as an anti-oxidant via its 
catalytic role in redox enzymes like thioredoxin reductase and glutathione 
peroxidase [72]. A selenium deficient diet leads to a constellation of syndromes 
including bone deformities, thyroid disorders, weakened immune response, and 
an endemic cardiomyopathy of the Keshan province in China [13-15]. Selenium 
also has a well-established history of anti-cancer and chemopreventive activity 
including its investigation in several large-scale human drug trials [20, 26, 27]. 
The anti-cancer or chemopreventive potential of selenium is highly dependent on 
the chemical species that is used, and a wide variety of organic and inorganic 
compounds have been studied. The discrepancy in efficacy of varying seleno-
compounds may have been responsible for the failure of the SELECT trial (which 
used pure selenomethionone and vitamin E, and thus further research into 
selenium toxicity is needed [27].  
Selenite (SeO32-) is one of the main inorganic forms of selenium that has 
shown promise as a chemopreventive and chemotherapeutic. Selenite has been 
shown to induce dose-dependent apoptosis in a variety of cancer types including 
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lung, prostate, glioma, and colorectal cancers [17, 24, 73, 74]. Recently, Park et 
al. uncovered evidence of ROS-mediated autophagy in A549 lung cancer cells 
eventually leading to cell death [22]. However, despite these findings, the exact 
mechanism of selenite-induced toxicity in cancer cells remains unclear. One of 
the main mechanistic theories involves the generation of ROS such as 
superoxide, hydrogen peroxide, and/or hydroxyl radical from the successive 
reduction of SeO32- to elemental selenium (Se0) [25]. The ROS generated can 
then induce DNA and protein damage that precipitates a cascade of events 
eventually leading to apoptosis and cell death. ROS accumulation and cell death 
are blocked in selenite-treated A549 cells by supplementation with N-
acetylcysteine (NAC), a commonly used antioxidant, which supports this 
mechanistic theory [22]. 
 Previously, using tracer-based experimental design Fan et al. showed that 
selenite treatment of A549 cells induces numerous metabolic alterations 
including disruption of the TCA cycle, glutaminolysis, and glycolysis [60]. The 
utility of stable isotope resolved metabolomics (SIRM) has also been 
demonstrated in establishing the differences between metabolic phenotypes of 
cancer and benign human lung tissues, the profiling of lipid biosynthesis in breast 
and lung cancer, and the non-steady state modeling of the hexosamine 
biosynthetic pathway in prostate [33, 55, 56]. Here, I employed SIRM as an 
approach towards mechanistic understanding of selenite toxicity in human lung 
cancer models, specifically disrupted glutamine (Gln) metabolism. 
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 Gln is one of the main anapleurotic substrates of the TCA cycle and 
contributes in the synthesis of nucleotides, amino acids, hexosamines, and 
glutathione among other metabolites. Gln consumption is often increased in 
tumors and glutaminase (GLS) inhibition has been shown to induce apoptosis in 
kidney and lung cancer cells overexpressing MYC, the proto-oncogene that 
drives GLS expression [39]. We have also found that c-MYC expression is 
elevated in the majority of NSCLC tumors relative to adjacent benign tissue in 
our ongoing patient study. Since our previous findings indicated selenite 
disrupted Gln metabolism in A549 cells and the large body of literature 
surrounding Gln’s importance in tumor nutrition, I have focused on Gln 
metabolism as a possible source of toxicity in A549 cells [23].  
GLS exists as two main isoforms in mammals, GLS1 and GLS2 [75]. 
GLS2 or liver type GLS (LGA) is partially regulated through interaction with Tax 
interacting protein (TIP-1) via its C-terminal domain and has been implicated as a 
tumor supressor [76, 77]. However, differences in the C-terminal domain of GLS1 
prohibit interaction with TIP-1 [78]. GLS1 can be subdivided into two splice 
variants, kidney type GLS (KGA) and GLS C (GAC). GAC is a splice variant of 
KGA that has been shown to be upregulated at the mRNA level in a variety of 
cancers including those of brain, colorectal, and breast [79-82]. GAC was 
recently shown to be localized exclusively in the mitochondria and is activated by 
inorganic phosphate [83]. GAC expression is regulated at least in part via c-MYC 
and interestingly has also been shown to be a target of mitochondrial Lon 
protease mediated degradation when modulated by diphenylarsenic acid [84, 
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85]. These recent findings along with this study suggest an increasingly important 
role for GAC in tumor metabolism and selenite mediated anti-cancer activity. 
 
3.2 Methods 
Cell culture: A549 cells were grown in glucose-free, glutamine-free DMEM 
medium supplemented with 10% FBS, 0.2% glucose, 4 mM glutamine, and 100 
I.U./mL penicillin 100 µg/mLstreptomycin at 37 °C and 5% CO2. Na2SeO3 
solutions were prepared immediately prior to use and sterilized using 0.22 µm 
syringe filter. Cells were grown to 70% confluence for all experiments. Two hours 
prior to treatment, medium was aspirated and replaced with half volume of the 
tracer medium. The remaining medium was then added with doubled Na2SeO3 
concentration in order for cells to be conditioned with the tracer medium prior to 
treatment.  
 
Tissue slices: During NSCLC surgical resection, very thin slices (0.5-1 mm) were 
prepared from tumor and adjacent benign tissue by the operating surgeon (Dr. M. 
Bousamra II). Tissue slices were immediately placed in T-25 culture flasks with 8 
mL DMEM medium supplemented with 10% FBS, 100 I.U./mL penicillin 100 
µg/mLstreptomycin, 0.2% glucose, and 4 mM Gln. Either 13C6-glucose or 
13C515N2-Gln was used for tracer experiments. Slice medium was then treated 
with or without 6.25 µM Na2SeO3. Flasks were then placed on a rotator in a cell 
culture incubator at 37 °C and 5% CO2 for 24 h. After 24 h, medium was collected 
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for downstream analysis, and tissue slices were washed with PBS before flash 
freezing in LN2.  
 
Extraction of metabolites: At the time of harvest, medium was collected before all 
plates were washed three times with ice cold PBS, and PBS was removed as 
much as possible by aspiration. The cells’ metabolism was then quenched with 1 
ml of CH3CN kept at -20°C before 0.75 ml of nanopure water was added and 
cells were harvested by scraping. The process was repeated once before CHCl3 
addition to a final CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, non-
polar and insoluble proteinaceous interface fractions for downstream analysis 
[65, 66]. For extraction of metabolites from human tissue slices, frozen tissue 
was first pulverized to powder in a liquid nitrogen freezer mill. The frozen powder 
was then extracted using the same ratio of CH3CN:H2O:CHCl3 detailed above. 
 
Glutaminase assays: For assaying whole cell glutaminase activity, cells were 
washed with PBS, trypsinized, and flash frozen in lN2. Cell pellets were 
resuspended in and then sheared via aspiration through a 28.5 gauge syringe. 
The assay solution consisted of cell lysate, 5 mM alpha-ketoglutarate, 200 mM 
KH2HPO4, 0.2 mM EDTA, 48 U/mL glutamate dehydrogenase (GDH), 0.3 mM 
NADH, and 20 mM Gln. The reaction was initiated with Gln and the absorbance 
was measured continuously at 340 nm for 20 min. Specific activity was then 
calculated from the change in the amount of NADH produced (derived from A340 
and molar absorptivity) over time. For mitochondrial activity assays, mitochondria 
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preparations described below were used. The assay solution consisted of 0.2 
mM Tris acetate pH 8.6, 20mM K2HPO4, 2mM NAD+, 15U/mL GDH, and 50mM 
Gln, Reaction was initiated with Gln and 5 µg total protein was used per reaction. 
Absorbance was then measured, and specific activity calculated as above. 
 
Mitochondrial isolation: Cells were washed with PBS, trypsinized, and pelleted 
before resuspending in 200 mM mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM 
HEPES pH 7.5. A protease and phosphatase inhibitor cocktail was added 
immediately prior to isolation as follows: HALT protease inhibitor cocktail (Pierce 
Biotechnology), 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 2 mM 
imidazole, and 1.15 mM Na molybdate. Cells were homogenized with 28.5 g 
needles and then centrifuged at 1000 g for 10min. Supernatant was collected 
and spun at 10,000-15,000 g for 15 min. Pellet was washed with 1 mL isolation 
buffer, centrifuged at 15,000 g for 15 min, and suspended in 25 mM HEPES, 150 
mM NaCl, 1 mM EDTA, and 0.01% triton X-100.  
 
NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1 
T instrument equipped with 5 mm HCN cold probe. Cell extracts were dissolved 
in D2O with 30 nmol d6-DSS, respectively, as internal standard. Shigemi tubes 
were used for polar extracts to minimize sample volume and thus to concentrate 
the metabolites. 1D proton spectra were recorded with an acquisition time of 2 
seconds after initial presaturation of the H2O signal with a recycle time of 5 
seconds. 1D 13C-filtered HSQC spectra were measured using an acquisition time 
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of 150 ms. 1D proton spectra were processed using a 1 Hz exponential line 
broadening function and a zero fill of 128 k points. 1D 13C-filtered HSQC spectra 
were processed with a 6 Hz line-broadening exponential and 0.07 Hz Gaussian 
functions and zero filled to 16 k points. Both types of spectra were processed 
manually for baseline and phase corrections. 1D proton spectra were referenced 
using the methyl signal of D6-DSS at 0 ppm, and 1D 13C-filtered HSQC spectra 
were referenced to the C4-Gln peak at 2.43 ppm. Metabolites were identified in 
reference to an in-house standard database and quantified by calibration with the 
methyl resonance of the DSS internal standard using the MestReNova NMR 
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59].  
 
GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% N-
tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-
Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS 
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion 
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized 
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary 
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness. 
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60 
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp; 
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan 
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time 
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified 
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using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM. 
All samples and standards were spiked with 1 µM norleucine as internal 
standard. 
 
Western Blot: At time of harvest cells were lysed directly on the plate using 62.5 
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein 
concentration was measured via the BCA method (Pierce). All protein extracts 
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1 
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and 
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein 
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a 
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then 
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer 
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF 
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room 
temperature in an Invitrogen transfer apparatus. All primary antibodies were 
incubated with membrane at 4 °C on a rocker overnight as follows: KGA (c-
terminus specific, Abnova), 1:2000 in PBST with 5% non-fat powdered milk; GAC 
(generously donated from Dias) 1:3300 in PBST; α-tubulin (Epitomics), 1:50,000 
in PBST with 5% non-fat powdered milk. Membranes were then washed 3 times 
with PBST before incubating 1 hour at room temperature with an HRP-
conjugated secondary antibody (Pierce, 1:2000 in PBST with 5% non-fat 
powdered milk). Blots were then incubated in Pierce supersignal extended 
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duration chemiluminescent reagent before exposure to x-ray film (SCBT) for 
visualization. Expression was then quantified using ImageJ software. 
 
RT-qPCR: At time of harvest, total RNA was extracted from cells using Trizol 
reagent (Invitrogen) and protocol. RNA concentration and quality were 
determined via absorbance on a Nanodrop instrument (Thermo Fisher), and 
integrity was verified via agarose gel electrophoresis. cDNA was synthesized 
using Invitrogen Superscript VILO cDNA synthesis kit. Primers for GAC and KGA 
were designed and purchased through IDT and β-actin through Qiagen. SYBR 
Green qPCR mastermix was purchased through Applied Biosystems. Primer and 
template concentrations were optimized for amplification efficiencies >90% 
before continuing with experimental assays. For quantification the ΔΔCt method 
was applied with β-actin as the housekeeping gene.  
 
Microscopy: A549 cells were grown to ~70% confluence in 6-well plates 
containing sterilized cover slips before treating with 6.25 mM Na2SeO3. At 3, 6, 
24 and 48 hours medium was aspirated. For ROS measurement 10 mM H2-
DCFDA (Molecular Probes) in 1 mL fresh medium was added to each well and 
incubated at room temperature for 20 min. Medium was then replaced with 3 mL 
fresh medium and cells were incubated for another 30 min at room temperature 
to allow dye to hydrolyze. Cover slips were then washed with fresh medium, and 
slides were placed face down onto slides pre-loaded with 20 mL PBS. Cover slip 
edges were then sealed with fingernail polish. For mitochondrial staining 25-100 
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nM MitoTracker Red (Molecular Probes) in 1 mL fresh medium was added to 
each well and incubated at 37 °C for 0.5-1 hour. Coverslips were then washed 
with fresh medium before placing on slide and sealing as above. Images were 
recorded on an Olympus BX51 fluorescence microscope using a 100x /1.3 Ph3, 
oil immersion lens (Olympus, Melville, NY) and appropriate filters (Omega 
Optical, Brattleboro, VT). 
 
Proliferation assays: Proliferation was measured in A549 according to the 
protocol by Raspotnig et al. [64]. Briefly, at the time of measurement cell medium 
was aspirated and replaced with minimal volume of 50% ethanol in H2O for 30 
min. Ethanol was then aspirated and replaced with minimal volume of 0.2% 
Janus green dye in PBS for 5 min. Dye was aspirated and plates were rinsed in 
RO H2O and then air-dried. Dye was then dissolved in 0.5 N HCl and absorbance 
was measured at 595 nm. 6.25 µM Na2SeO3 and 5mM Glu was used for all 
proliferation assays. For rescue experiments, Glu and/or selenite were 
introduced to media simultaneously and growth was quantified as the fraction of 
absorbance over day 0. 
 
Statistics: All metabolite amounts were normalized to total protein measured via 
the BCA method. All error bars represent the standard deviation of an average of 
experiments (the specific number of experiments is provided in appropriate figure 
legends). For statistical significance of experiments where only a single variable 
was measured (i.e., enzyme activity assay) the two-tailed Student paired t-test 
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was used to calculate p values, and p values <0.05 were considered significant. 
For experiments involving multiple measurements (i.e., measurement of 
metabolites from NMR and MS analysis) the false discovery rate method 
described by Benjamini and Hochberg was applied [67].  Briefly, naïve p-values 
for all measured metabolites were calculated. These values were then ranked in 
order of decreasing significance and assigned a rank number. A qi value was 
then calculated according to the equation qi=kpi/i where i=rank of the p value 
among the k tests. The false discovery rate (FDR) was then defined for every qi 
value such that FDRi=min(qi,…,qk). Tests with p values <0.05 and an FDR value 
<0.05 were then accepted as significant. For cell-based experiments, only Glu, 
Gln, GSG, and GSH were measured for statistical differences among treatments. 
For tissue experiments Glu, fumarate, malate, and Asp were measured. 
 
3.3 Results and Discussion 
3.3.1 Selenite disrupts Gln utilization in human lung cancer models 
3.3.1.1 Cell culture 
In order to probe SeO32- perturbed metabolism in cancerous and non-
cancerous lung models, A549 human lung cancer cells and non-transformed 
NHBE cells were treated with or without 6.25 µM Na2SeO3, and metabolites in 
polar extracts were measured using NMR and MS. An immediately obvious 
feature of the polar metabolic profiles from SeO32- treated A549 cells was the 
buildup and depletion of Gln and Glu, respectively, as illustrated in figure 3.1.  












Figure 3.1.  Effect of selenite on Gln metabolism.  
1D proton spectra were recorded of polar extracts of A549 and NHBE cells treated for 24 hours 
with 6.25 µM Na2SeO3. Spectra were superimposed and normalized to total protein to assess 
differences between treatments. Selected region displays the C4 protons from both Gln and Glu. 
 
Figure 3.2. Gln and Glu quantification from selenite treated A549 cells.  
A) 1D proton spectra were recorded from the polar extracts of A549 cells treated with 6.25 µM 
Na2SeO3 for 24 hours. C4-Glu and Gln proton peaks at 2.34 and 2.44 ppm were quantified and 
normalized to total protein. *p<0.001; n=3. B) Total Gln and Glu normalized to total protein were 






However, little to no effect on Gln or Glu was apparent in the corresponding 
spectra of NHBE cells treated with the same concentration of SeO32- (Fig. 3.1).   
Time course GC-MS measurements taken from SeO32- treated A549 cells 
indicated that Gln and Glu levels began to increase and decrease, respectively, 
at ~3 h of treatment and these changes continued for the duration of the 
experiment (Fig. 3.2B). By ~6 h of selenite treatment, Glu depletion had 
plateaued with a half-life of ~2 h, while Gln continued to accumulate suggesting 
inhibition of the glutaminase reaction that converts Gln to Glu while maintaining 
Gln import.  
In order to further probe altered glutaminolysis in cell experiments, 
13C515N2-Gln was utilized as a tracer in time course experiments to directly 
measure the conversion of Gln to Glu and downstream metabolites. 1D 13C- 
filtered HSQC spectra were recorded  of the polar extracts of SeO32- treated 
A549 cells to follow the time course changes in 13C-labeled metabolites. 
Consistent with findings from the unlabeled experiments, the selenite-induced 
13C-Gln buildup/Glu depletion began at ~3 h and the same trend continued 
thereafter (Fig. 3.3). Selenite also elicited a depletion of 13C-labeled glutathione  
beginning at ~6 h of the treatment and a depletion of 13C-labeled Asp and citrate 
beginning at ~3 h of treatment,  as illustrated in figure 3.3. Furthermore, the level 
of downstream products of 13C5,15N2-Gln via glutaminase and the Krebs cycle, 
i.e. 13C5,15N1-Glu, 13C4-fumarate, 13C4-malate, and 13C4,15N1-Asp showed a 
progressive decrease with selenite treatment, which began at ~3h to near non-
detectable by 24h (Fig. 3.4). The corresponding metabolites in the controls  
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Figure 3.3. Time course effect of selenite on Gln, Glu, and glutathione 
1D 1H[33] HSQC spectra were recorded from polar extracts of A549 cells pre-incubated for 2 
hours with 13C5,15N2-Gln tracer and treated with or without 6.25 µM Na2SeO3 for 0, 1.5, 3, 6, 11, 
and 24 hours. Control and selenite spectra were superimposed and normalized to total protein to 
visualize differences between treatments in 13C-4-glutathione, 13C-4-Gln, and 13C-4-Glu at 2.54, 










Figure 3.4. Time course quantitation of selenite effects on Gln-derived metabolites in A549 
GC-MS spectra were recorded from A549 cells treated pre-incubated for 2 hours with 13C5,15N2-
Gln tracer and treated with or without 6.25 µM Na2SeO3 for 0, 1.5, 3, 6, 11, and 24 hours. 
13C5,15N1-Glu, 13C4-malate, 13C4-fumarate, and 13C4,15N1-Asp were quantified and normalized to 







continued to increase for the duration of the experiment, possibly because the 
TCA cycle had not yet reached isotopic steady state. Fluctuations at 2 h may be 
due to equilibration of metabolism to medium change.  
3.3.1.2 Human Tissue Slices 
Thin (0.5-1 mm) slices of tumor and adjacent benign lung tissue from 
human non-small cell lung cancer (NSLSC) surgical patients were used as an 
individualized model for human lung cancer. These tissue slices are analogous to 
those described by Warburg, but are placed in medium rather than on wet 
blotting paper, thereby giving much greater control over nutrient supply and 
removal of waste products [29]. Such slices represent better models than 
cultured cells as they contain much of the in situ microenvironment that is lost 
with cell cultures. Including the orginal tissue architecture and the stromal cells of 
the tumor. These tissue slices were treated with or without 6.25 µM Na2SeO3 in 
the presence of 13C5,15N2-Gln for 24 h. As shown in the 1D 13C-filtered HSQC 
spectra of figure 3.5A, the 13C-labeled Gln/Glu buildup/depletion observed in the 
cell experiments was recapitulated in the lung tumor slices but much less so for 
the benign counterpart. Quantification of the 13C-Gln and Glu from the spectra 
yielded signicantly elevated Gln/Glu ratios induced by selenite in the cancerous 
tissues over the benign tissues, consistent with impaired glutaminolysis (Fig. 
3.5B). Downstream metabolites of 13C5,15N2-Gln (13C5,15N1-Glu, 13C4-fumarate, 
13C4-malate, and 13C4,15N1-Asp) were also measured in cancerous and benign 
human tissue slices treated with selenite for 24 h. The reduction of labeled Glu, 








Figure 3.5. Effect of selenite on Gln/Glu ratio in NSCLC surgical patient tissue slices 
A) 1D 1H[33] HSQC spectra recorded from polar extracts of benign and cancerous human tissue 
slices labeled with 13C5,15N2-Gln tracer and treated with or without 6.25 µM Na2SeO3 for 24 hours. 
Control and selenite spectra were superimposed and normalized to total protein in order to 
visualize differences between treatments. B) Gln/Glu peak area ratios were calculated. *p<0.001,  
#p<0.05 for the increase in Gln/Glu in selenite treated cancer tissue slices with respect to non-










not as dramatic as in the cell experiments (Fig. 3.6). Benign tissues also 
responded to selenite treatment, albeit to a lesser extent, suggesting that there is 
some impact on glutaminolysis in the surrounding non-cancerous tissue. Smaller 
differences, however, are to be expected between tumor and benign tissue than 
in pure cell culture due to the presence of stromal cells in both tissue 
environments and inflammation in the lung. 
 3.3.2 Selenite inhibits GLS activity by decreasing its expression 
 Since the tracer-based metabolic characterization of SeO32- treated lung 
cancer models strongly suggested inhibited glutaminolysis, I then probed the 
glutaminase (GLS) activity directly by utilizing a coupled GLS-GDH colorimetric 
enzyme assay (Fig. 3.7).  GLS activity was significantly reduced under selenite 
treatment by 6 h, which continued for 24 hours. In order to determine if enzyme 
activity was modulated through direct or allosteric means, I measured GLS 
activity in crude A549 lysates subsequently treated with 6.25 µM Na2SeO3 for 
various times. However, only a weak dose response decrease in activity was 
observed (Fig. 3.8). We then measured the specific activity of purified GAC 
isoform treated with 6.25 µM Na2SeO3 and again noted no change in activity (Fig. 
3.9).  
In order to determine if selenite exerted its inhibitory effect via enzyme 
expression, I then measured levels of the kidney (KGA) and GAC isoforms of 
GLS from selenite-treated A549 cells via western blot (Fig. 3.10). Interestingly, 
KGA levels remained largely unchanged while GAC expression was greatly 










Figure 3.6. Quantitation of selenite effects on Gln derived metabolites in in NSCLC surgical 
patient tissue slices 
Polar metabolites were extracted and quantified from tumor and adjacent benign tissue slices 
incubated with13C5,15N2-Gln and treated with or without 6.25 µM Na2SeO3 for 24 hours. 
Downstream metabolites of Gln were quantified via GC-MS and normalized to total protein before 
determining ratios. *’s represent a significant reduction in the selenite-treated cells compared to 










Figure 3.7. Time course changes in GLS activity of control and SeO3 treated A549 cells 
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested at 0, 1.5, 3, 6, 11, and 
24 h after treatment. Mitochondria were isolated and assayed for GLS activity as described. 













Figure 3.8. Time course changes in GLS activity of selenite-treated A549 cell lysate 
A549 lysates were pooled and treated with increasing concentrations of Na2SeO3 for 0, 3, 6, 10, 
and 24 h before assaying for GLS activity. Activity was normalized to total protein determined via 










Figure 3.9. Effect of selenite on purified GAC activity 
5 mg of purified GAC were treated with increasing concentrations of Na2SeO3 for 0, 3, 6, 10, and 




















Figure 3.10. Effect of selenite on GAC and KGA expression in A549 
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested 0, 1.5, 3, 6, 9, and 24 h 
after treatment. Protein was extracted and processed for GLS expression as described. A) 
Representative western blot from selenite-treated A549 time course experiment illustrating GAC 
and KGA expression. B) Quantification of GAC and KGA normalized to α-tubulin and expressed 







activity measurements shown in Figure 3.7. GAC and KGA expression was then 
measured in selenite-treated NHBE cells to determine if the effect matched that 
seen in A549 (Fig. 3.11). In agreement with the NMR spectra from figure 3.1 
GAC expression was unchanged by selenite; however, baseline expression was 
decreased relative to A549, suggesting that cancer cells may require increased 
levels of GAC for proliferation. Furthermore, the data also imply that reduction of 
GAC expression may be partly responsible for the cancer-specific cytotoxicity 
observed with selenite treatment. Finally, I then examined GAC and KGA 
expression in selenite-treated tumor and adjacent benign tissue slices. 
Interestingly, the GAC expression was dramatically reduced in both tumor and 
adjacent benign tissue by selenite, recapitulating the A549 response and 
suggesting that GAC loss and/or glutaminolysis in the benign tissue is not as 
damaging as it is in tumor (Fig. 3.12). Furthermore, KGA expression was 
essentially unchanged by selenite treatment as in A549 cells. Despite unchanged 
KGA expression, the increased Gln/Glu ratio in figure 3.5 suggests that adequate 
glutaminase activity was not being supplied. 
Total RNA was then harvested from parallel selenite-treated A549 time 
course experiments in order to quantify KGA and GAC mRNA via RT-qPCR and 
to determine if the decrease in GAC expression was transcriptionally regulated 
(Fig. 3.13). However, no difference in KGA or GAC mRNA relative to 






















Figure 3.11. Effect of selenite on GAC and KGA expression in NHBE 
NHBE and A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested 24 h after 
treatment. Protein was extracted and processed for GLS expression as described. A) 
Representative western blot from selenite-treated A549 and NHBE cells illustrating GAC and 
KGA expression. B) Quantification of GAC and KGA normalized to α-tubulin and expressed as 





3.3.3 Selenite-induced glutathione perturbations and ROS damage 
 As selenite is known to induce oxidative stress, GSSG/GSH ratios were 
also measured from the NMR spectra of selenite-treated A549 polar extracts as 
indicators of oxidative stress. The GSSG/GSH ratio was ~4-fold higher than 
controls after 24 h of selenite treatment in A549 cells (Fig. 3.14). Mitochondrial 
and ROS fluorescence were also measured in micrographs of selenite-treated 
A549 cells as another indicator of oxidative damage (Fig 3.15). ROS 
accumulation was evident as early as 3 h and increased dramatically by 24h. 
3.3.4 Glu rescue experiment 
 We then postulated that the decrease in GAC expression and consequent 
depletion of Glu and downstream metabolites induced by selenite was 
responsible for the decreased total glutathione levels, increased GSSG/GSH 
ratios, and increased ROS production. In order to test this hypothesis we treated 
A549 cells with 6.25 µM Na2SeO3 in the presence or absence of 5 mM Glu. By 
supplying the cells with the direct product of the GAC reaction we expected to 
mitigate the anti-proliferative effects of selenite. Indeed, in the presence of Glu, 
the proliferation of selenite-treated A549 cells was substantially rescued, as 
measured via Janus green proliferation assay (Fig. 3.16). Interestingly, Glu 
















Figure 3.12. Effect of selenite on GAC and KGA expression in NSCLC surgical patient 
tissue slices 
A) Representative western blot from selenite-treated tumor (T) and adjacent benign (B) NSCLC 
patient tissue. B) Quantification of GAC and KGA normalized to tubulin and expressed as SeO3-















Figure 3.13. Relative fold change of KGA and GAC mRNA.  
A549 cells were treated with or without 6.25 µM Na2SeO3 and harvested at 0, 1.5, 3, 6, 11, and 
24 h after treatment. Total RNA was extracted and measured as described. ddCt values were 
calculated with b-actin as housekeeping gene. Fold changes were then calculated and are shown 










Figure 3.14. Quantitation of GSSG/GSH in selenite treated A549 cells 
1D proton spectra were recorded from the polar extracts of A549 cells treated with or without 6.25 






Figure 3.15. Effect of selenite on ROS in A549 cells  
A549 cells were treated with or without 6.25 µM Na2SeO3 and prepared for ROS measurement as 
described at 3, 6, 24, and 48 h after treatment as described. Red stain indicates mitochondria and 
















Figure 3.16. Glu rescues the proliferative phenotype in selenite-treated A549 cells 
 A549 cells were treated with or without 6.25 µM Na2SeO3 +/- 5 mM Glu and measured for growth 
via Janus green assay 0, 1, 2, and 3 days after treatment as described. Fractional growth was 
calculated as the absorbance at day n divided by absorbance at day 0. Fractional growth is 
plotted as selenite-treated cells +/- Glu divided by the fractional growth of non-treated controls. 
*p<0.001; n=5  
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3.4 Conclusions 
These experiments illustrate a novel mechanism for selenite-induced ROS 
accumulation in A549 cells. Examination of the metabolic profiles generated from 
selenite-treated A549 showed significantly elevated Gln and depleted Glu  
consistent with decreased glutaminase activity. This effect on glutaminase was 
selective towards cancer cells as Gln and Glu levels in non-transformed NHBE 
cells were substantially less affected. By utilizing a tracer-based experimental 
design with 13C5,15N2-Gln we then showed that anapleurosis of the TCA cycle 
through glutaminolysis was dramatically attenuated by selenite treatment. 
Depletion of labeled glutaminolytic metabolites from 13C5,15N2-Gln occurred 
rapidly within 3 hours of treatment. We then repeated these experiments in an 
individualized lung cancer tissue slice model, which recapitulated impaired 
glutaminolysis substantially moreso in the cancer than in the adjacent benign 
tissue. Treatment with selenite caused a time-dependent decrease in GAC 
protein expression without impacting transcription levels or enzyme specific 
activity indicating that selenite affects either the translation or degradation rate. 
Interestingly, KGA was unchanged by selenite treatment suggesting that the 
GAC splice variant is vital for cancer growth and viability. Furthermore, GAC 
expression was also decreased in selenite treated tissue slices from four 
separate NSCLC patients.  
Gln is one of the main anapleurotic substrates contributing towards 
anabolism including glutathione synthesis. We showed that selenite treatment 
substantially decreased newly synthesized glutathione as well as increased the 
	  109	  
ratio of GSSG/GSH. Presumably, the decrease in glutathione synthesis stems 
from impaired glutaminolysis which is needed to supply glutamate, and could 
contribute towards increased GSSG/GSH as reduced glutathione is consumed. 
As A549 cells rapidly proliferate, GSH must be synthesized continually in order to 
maintain steady-state levels and replenish stores lost through non-oxidative 
means; however, selenite blocks this process by inhibiting glutaminolysis.  
Increased ROS production in the presence of selenite overwhelms the capacity 
of the GPX/GR/NADPH systems, leading to increased GSSG/GSH.  The 
resulting high ROS may initiate autophagic and apoptotic pathways, further 
increasing ROS [22]. Preventing this cascade of events would require providing 
the necessary reducing equivalents for the surge in ROS. Park et al. [22] showed 
that exogenous NAC supplied these reducing equivalents; however, we found 
that supplying the cells with Glu restored proliferation as well. This suggests that 
impaired glutaminolysis via decreased GAC expression is one of the primary 




CHAPTER 4-GLYCOGEN IS AN IMPORTANT FUEL 
SOURCE FOR LUNG CANCER 
4.1 Introduction  
Glycogen is a polymeric storage form of glucose in mammalian tissues, 
particularly in liver and skeletal muscle. It is a highly branched polymer, 
comprising linear chains of α−1,4 linked glucose subunits, with α-1,6 branch 
points, and is stored in granules in the cytoplasm. Glycogen synthesis consumes 
an ATP equivalent (via the activation step of G1P+UTP->UDPGlc + Pi). 
Glycogen is mobilized through glycogenolysis via glycogen phosphorylase (PYG) 
and the debranching enzyme, which can liberate glucose-1-phosphate (G1P) 
during fasted or exerted states when blood glucose is low. G1P is readily 
isomerized to G6P without the consumption of ATP. Thus, glycogenolysis 
followed by glycolytic transformation to pyruvate generates 3 ATP molecules per 
molecule of glucose oxidized.  
Glycogen metabolism is generally tightly regulated through both insulin 
and epinephrine-dependent and independent mechanisms acting reciprocally 
through glycogen synthase and glycogen phosphorylase [86]. There is a well-
characterized clinical history of disorders in glycogen metabolism typically 
classified as the glycogen storage diseases. Glycogen storage diseases typically 
manifest with varying clinical severity and a pathophysiology stemming from 
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mutations in the three main isoforms of glycogen phosphorylase (GPase), which 
are the brain or fetal (PYGB), liver (PYGL), and muscle (PYGM) variants [87, 88].  
 Glycogenolysis is also of burgeoning interest in the context of cancer 
metabolism. PYGB was the main isoform expressed in 59 cancer cell lines 
including A549, whose growth was reduced via pharmacological inhibition of 
PYGB [89]. Furthermore, glycolytic models have indicated that glycogen 
degradation is an integral process for controlling flux through glycolysis under 
glucose-deprived tumor environments [90]. Glycogenolysis also seems to be 
closely tied to UDP-GlcNAc regulation as was illustrated by a glycogen-derived 
increase in O-GlcNAc modification of proteins in response to glucose deprivation 
[50].  Furthermore, the brain isoform of GPase is less sensitive to regulation by 
phosphorylation than either the liver or muscle isoforms, but is strongly activated 
by AMP, making it an energy-sensing enzyme [29] 
 In order to further elucidate the anti-cancer potential of glycogen 
phosphorylase inhibition and obtain detailed understanding of its metabolic basis 
I utilized SIRM-based experimental design to evaluate the metabolic effect of 
PYGB suppression in A549 cells. This target was also chosen to follow up on the 
reduction of glycogen synthesis that was observed in selenite-treated lung 
cancer tissue. I chose to focus on PYGB because it is the isoform that is primarily 
expressed in A549 cells and its relevance with regards to growth inhibition in 
cancer cells [91]. Finally, its role in UDP-GlcNAc metabolism is unclear and thus 




Cell culture: A549 and 293T cells were grown in glucose-free, glutamine-free 
DMEM medium supplemented with 10% FBS, 0.2% (A549) or 0.45% (293T) 
glucose, 4 mM glutamine, and 100 I.U./mL penicillin 100 µg/mL streptomycin at 
37 °C and 5% CO2. For tracer experiments, cells were grown to ~70% 
confluence, and medium was aspirated and replaced with the tracer medium 
containing 0.2% 13C6-glucose (10.8 mM) (Sigma Isotec, St. Louis. MO). For 
western blots, cells were lysed directly on the plate using 62.5 mM Tris, 2% SDS 
buffer at pH 6.8 before harvest by scraping and protein concentration was 
measured via the BCA method (Pierce).  
 
Lentiviral PYGB suppression: 293T cells generously donated by Dr. Mariia 
Yuneva were grown to ~50% confluence in 6-well plates before transfecting with 
shRNA constructs. One h prior to transfection, medium was replaced with fresh 
medium. 0.3 µg pMDG (Yuneva), 0.6 µg pCMV (Yuneva), 1.2 µg shRNA, and 10 
µL X-tremeGENE HP transfection reagent (Roche, Mannheim, Germany) were 
mixed with OPTIMEM (Invitrogen) medium to a total volume of 110 µL per well 
(6-well plate) and incubated for 20 min at room temperature before applying to 
wells dropwise. shPYGB’s and the empty vector (shEV,Mission® shRNA, Sigma, 
St. Louis, MO).) (Sigma) had the following sequences: sh339, 
CCGGGCTATGGAATCCGCTATGAATCTCGAGATTCATAGCGGATTCCATAG
CTTTTTTG; sh479, CCGGGATCGTGAAACAGTCGGTCTTCTCGAGAAGACCG 
ACTGTTTCACGATCTTTTTTG; sh010, CCGGCACGAAGAAGACCTGTGCATA 
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CTCGAGTATGCACAGGTCTTCTTCGTGTTTTTTG. About 12 h after applying 
transfection reagents, medium was again replaced with fresh medium. 
Transduction of A549 cells occurred ~48 h after transfection of 293T cells. In 
preparation, A549 cells were grown to ~50% confluence and medium was 
replaced immediately prior to transduction. Viral medium from 293T cells was 
collected and filtered using a 0.22 µm syringe filter before adding 16 µg/mL 
polybrene (Sigma). The filtered medium was then applied to wells dropwise 
(polybrene final concentration, 8 µg/mL). Fresh medium was added to 
transfected 293T cells for repeating the transduction procedure 24 h later. After 
24 h of the final transduction, A549 medium was replaced with fresh medium. 48-
72 h after transduction, A549 cells were selected using medium supplemented 
with 1 µg/mL puromycin (Sigma). 
 
Proliferation assays: Proliferation of A549 cells was measured in 96-well plates 
according to the protocol by Raspotnig et al. [64]. Briefly, at the time of 
measurement, cell medium was aspirated and replaced with 50% ethanol in H2O 
for 30 min. Ethanol was then aspirated and replaced with minimal volume of 
0.2% Janus green dye in PBS for 5 min. Dye was aspirated and plates were 
rinsed in tap H2O and drained by gravity. Dye was then dissolved in 0.5 N HCl 
and absorbance was measured at 595 nm at 0, 24, 48, and 72 h of growth. 
Growth was reported as the fraction of the absorbance at a given time point 
divided by the absorbance at 0 h.  
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Colony formation assay: One % agarose in H2O was melted in a microwave to 
sterilize and then mixed with equal volumes of pre-warmed 2X DMEM cell culture 
medium. One mL of the mixture was then quickly added to each well of a 6-well 
culture plate and allowed to solidify at room temperature. After bottom layer had 
solidified, 3% agarose in PBS was melted in a microwave and allowed to partially 
cool. Cells to be assayed were trypsinized, counted, and diluted to 11,000 
cells/mL in pre-warmed DMEM culture medium. The cell suspension was then 
quickly mixed with 3% agarose at a ratio of 10:1 suspended cells:agarose, and 1 
mL of the resulting mixture was immediately added on top of the bottom agarose 
layer without disruption of the bottom layer or bubble formation. The top layer 
was then allowed to solidify for 30-60 min at room temperature. After 
solidification, 1 mL of DMEM culture medium was then carefully added to each 
well to avoid disturbing the agarose. Once a week, medium was carefully 
replaced via aspiration, again to avoid agarose disruption. After ~2 weeks or 
when colonies had grown sufficiently, medium was aspirated and wells were 
stained with 0.005% crystal violet in PBS for >1 h. Colonies (>8 aggregated cells) 
were digitally documented for colony size and shape and counted for 20 random 
fields of view. 
 
Extraction of metabolites: Transduced A549 cells were seeded in 10 cm plates 
and grown until the shEV-transduced cells reached ~90% confluence for harvest.  
At the time of harvest, medium was collected before all plates were washed three 
times with ice cold PBS, and PBS was removed as much as possible by 
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aspiration. The cells’ metabolism was then quenched with 1 ml of CH3CN kept at 
-20°C before 0.75 ml of nanopure water was added and cells were harvested by 
scraping. The process was repeated once before CHCl3 addition to a final 
CH3CN:H2O:CHCl3 ratio of 2:1.5:1 to obtain the polar, non-polar and insoluble 
proteinaceous interface fractions for downstream analysis [65, 66]. For 
metabolite extraction from the medium, protein was first precipitated in ice-cold 
10% trichloroacetic acid (TCA), and supernatant was lyophilized immediately to 
remove the acid. Since some metabolites such as glutamine are sensitive to 
prolonged storage in acidic conditions, metabolite analysis of medium samples 
by NMR or GC-MS was performed immediately after lyophilization. 
 
NMR experiments: All NMR experiments were conducted on a Varian Inova 14.1 
T instrument equipped with 5 mm HCN cold probe. Cell and medium extracts 
were dissolved in D2O with 30 and 50 nmol d6-DSS, respectively, as internal 
standard. Shigemi tubes were used for polar extracts to minimize sample volume 
and thus to concentrate the metabolites. 1D proton spectra were recorded with 
an acquisition time of 2 seconds after initial presaturation of the H2O signal with a 
recycle time of 5 seconds. 1D 13C-filtered HSQC spectra were measured using 
an acquisition time of 150 ms. 1D proton spectra were processed using a 1 Hz 
exponential line broadening function and a zero fill of 128 k points. 1D 13C-filtered 
HSQC spectra were processed with a 6 Hz line-broadening exponential and 0.07 
Hz Gaussian functions and zero filled to 16 k points. Both types of spectra were 
processed manually for baseline and phase corrections. 1D proton spectra were 
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referenced using the methyl signal of D6-DSS at 0 ppm, and 1D 13C-filtered 
HSQC spectra were referenced to the C3-lactate peak at 1.32 ppm and 1.41 ppm 
for cell and medium extracts, respectively. Metabolites were identified in 
reference to an in-house standard database and quantified by calibration with the 
methyl resonance of the DSS internal standard using the MestReNova NMR 
processing software (Mestrelab Research, Santiago de Compostela, Spain) [59]. 
 
GC-MS analysis: An aliquot of the lyophilized extracts was derivatized in 50% N-
tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-
Butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl) in CH3CN before GC-MS 
analysis. All GC-MS data were acquired on a ThermoFinnigan PolarisQ GC-Ion 
trap MSn instrument (ThermoScientific, Rockford IL). One µL of the derivatized 
sample was separated on a SGE Forte (Victoria, Australia) 5% phenyl capillary 
column with the following dimensions: 50 m x 0.15 mm; 0.25 µm film thickness. 
The GC parameters were as follows: injector and transfer line, 280 °C; oven, 60 
°C for 2 min, 60 to 150 °C at 20 °C/min ramp, 150 to 300 °C at 6 °C/min ramp; 
He carrier gas with flow rate of 1.5 mL/min. Spectra were acquired in segscan 
mode with ranges of 140-206, 209-280, and 283-650 m/z with an acquisition time 
of 0.97 s. Spectra were processed using Xcalibur MS software and quantified 
using a mixture of 63 standards at 50 µM each except for glutamate at 500 µM. 




Nucleotide processing for FT-ICR-MS (Fourier transform-ion cyclotron 
resonance-mass spectrometry) analysis: Nucleotides were ion-paired with 
hexylamine and extracted from polar extracts as described previously [57]. 
Briefly, dried extract aliquots (e.g. 1/16 of one 10 cm plate) were dissolved in 5 
mM hexylamine in H2O (buffer A) with the pH adjusted to 6.3 with acetic acid. 
Dissolved nucleotides were adsorbed onto C18 ZipTips (Millipore, Billerica, MA) 
pre-conditioned with MeOH and buffer A. Bound nucleotides were then washed 
with buffer A followed by elution with 70% buffer A/30% buffer B (90% methanol 
and 10% 10mM ammonium acetate adjusted to pH 8.5 with aqueous ammonia). 
Eluent was then lyophilized and reconstituted in 2:1 MeOH:buffer B for FT-ICR-
MS analysis. 
 
FT-ICR-MS analysis: FT-ICR-MS analysis was performed as described 
previously [57]. Briefly, data were recorded on a hybrid linear ion trap–FT-ICR 
mass spectrometer (Finnigan LTQ FT, Thermo Electron, Bremen, Germany) 
using an automated nanospray ion source (TriVersa NanoMate, Advion 
BioSciences, Ithaca, NY) set with an “A” chip run at 1.5 kV and 0.5 psi head 
pressure. Measurements were recorded for 15 min, which consisted of 14 min of 
high resolution FT-ICR scans, followed by 30 s of low resolution ion trap scans 
(LTQ). FT-ICR-MS scans were recorded from 150-800 Da with a mass resolving 
power set to 400,000 at 400 m/z. Each transformed spectrum consisted of 5 
summed transients at 2 s per transient for a cycle time of 10 s. All FT-ICR-MS 
scans were summed to produce the final spectrum. Spectra were then exported 
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via Xcalibur MS software and peaks were corrected and assigned using an in-
house software (PREMISE  [56]). 
 
Western Blot: At time of harvest cells were lysed directly on the plate using 62.5 
mM Tris, 2% SDS buffer at pH 6.8 before harvest by scraping, and protein 
concentration was measured via the BCA method (Pierce). All protein extracts 
were diluted in 4X loading buffer (50% glycerol, 4% SDS, 150 mM Tris pH 6.8, 1 
mM DTT, 0.02% bromophenol blue, 10% β-mercaptoethanol) to 1X strength and 
then boiled for 10 minutes prior to electrophoresis. Approximately 30 µg protein 
was loaded for each sample onto a denaturing SDS 10 % acrylamide gel with a 
6% stacking gel. Protein extracts were stacked for 30 min at 100 V and then 
resolved for 1.5 h at 200 V using commercially available Tris/Gly/SDS buffer 
(National Diagnostics, Atlanta, GA). Proteins were then transferred onto a PVDF 
membrane (Immobilon-P, Millipore, Bedford, MA) at 25 V for 2 h at room 
temperature in an Invitrogen transfer apparatus. The transferred membrane was 
then incubated in the following primary antibody at 4 °C on a rocker overnight: 
PYGB (LSBio, Seattle, WA), 1:1000 in PBST with 5% BSA; α-tubulin (epitomics), 
1:50,000 in PBST with 5% non-fat powdered milk. Membranes were then washed 
3 times with PBST before incubating 1 hour at room temperature with an HRP-
conjugated secondary antibody (Pierce, 1:2000 in PBST with 5% non-fat 
powdered milk). Blots were then incubated in Pierce supersignal extended 
duration chemiluminescent reagent before exposure to x-ray film (SCBT) for 
visualization.  
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4.3 Results and discussion 
4.3.1 PYGB suppression inhibits growth and colony formation in A549 cells 
In order to determine if glycogen metabolism is important for supporting 
cancer cell proliferation, PYGB suppression in A549 cells was achieved using 
lentiviral transduction system and shPYGB vectors. Three different vectors were 
tested for their efficiency in PYGB suppression and effect on cell growth as 
shown in figure 4.1A. Sh339 and sh479 had the greatest effect on PYGB 
expression, while sh010 had much less impact (Fig. 4.1B). However, all three 
vectors had similar effects on proliferation, and by 72 h growth was attenuated by 
about 100%. Interestingly, sh010 exerted the strongest effect on proliferation 
despite having a slight effect on PYGB expression suggesting an off target 
mechanism of growth reduction. Colony formation assay was also performed as 
a surrogate analysis for tumorigenesis with these three vectors (Fig. 4.2). Sh479 
but not the other two vectors had a small but significant effect on colony 
formation, reducing the number of colonies by ~30% suggesting that PYGB may 
also be involved in tumorigenesis but has a greater effect on growth.  
4.3.2 PYGB-suppressed A549 cells accumulate glycogen and glucose 
The metabolic perturbations in these suppressed cells were investigated 
using 13C6-glucose as a tracer. The NMR spectra of polar metabolites for 
shPYGB and shENV samples showed a noticeable accumulation of unlabeled 
glycogen (5.4 ppm) and glucose (5.22 ppm) in sh339 and sh479-suppressed 















Figure 4.1. PYGB suppression inhibited A549 cell growth 
A549 cells were transduced with three different lentiviral shPYGB constructs along with an empty 
vector (shENV) as described in Methods. Growth was measured via Janus green assay five 
passages after transduction. Growth was plotted as fraction relative to day 0. B) PYGB 














Figure 4.2. PYGB suppression reduced A549 colony formation 
ShPYGB transduced A549 cells were assayed for colony formation after five passages. Bars 













Figure 4.3. PYGB suppressed A549 cells accumulated glycogen and glucose 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via 1D proton NMR. Spectra were normalized to 








13C1-glucose at 5.22 ppm) and glycogen (13C1-glycogen at 5.4 ppm) also 
accumulated in sh339 and sh479-transduced cells relative to the control cells as 
shown in the protein normalized HSQC spectra, which suggests increased 
glycogen synthesis and/or decreased utilization (Fig. 4.4). The latter is expected 
from the block of GPase activity from the PYGB knockdown. However, the NMR-
observable glycogen peak only represents the freely mobile reducing ends of 
glycogen, which may not fully represent the status of bulk glycogen. Namely, 
some of these C1-protons may be immobilized within the interior of the molecule 
and are not observable in 1H NMR analysis.  
Thus, to better visualize the total glycogen pool in these crude extracts, 
the extracts were hydrolyzed with 1M HCl at 65 °C for 10 min. Total glycogen 
was hydrolysed to free glucose, which was quantified by the peak at 5.22 ppm in 
the 1H NMR spectra. As shown in figures 4.5 and 4.6, there was an increase in 
the H1 glucose peak at 5.22 ppm in both the 1D proton and 1D 13C-filtered 
HSQC spectra of sh339 and sh479-suppressed cells, indicating glycogen buildup 
as expected with PYGB suppression. However, the effect of sh010 transduction 
differed, i.e. a significant increase in the level of acid-liberated 12C-glucose but 
not in that of 13C-glucose. This pattern suggests a buildup of unlabeled glycogen 
but not newly synthesized 13C-labeled glycogen consistent with a block in both 
glycogen hydrolysis and synthesis. Altogether, these data demonstrate selective 
suppression of PYGB by sh339 and sh479, while sh010 suppressed PYGB less 




Figure 4.4. PYGB suppressed A549 cells accumulated newly synthesized glycogen in A549 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via 13C-filtered 1D HSQC NMR. Spectra were 












Figure 4.5. Hydrolysis of polar extracts from shPYG suppressed A549 cells liberated 
unlabeled glucose units from glycogen 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and glycogen was hydrolyzed as described. HCl-liberated 
glucose was measured via 1D proton NMR, and spectra were normalized to total protein in order 







Figure 4.6. Hydrolysis of polar extracts from shPYG suppressed A549 cells liberated 
labeled glucose units from glycogen 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and glycogen was hydrolyzed as described. HCl-liberated 
glucose was measured via 13C-filtered 1D HSQC NMR, and spectra were normalized to total 







Because there was an increase in intracellular glucose levels with PYGB 
suppression, lactate production and glucose consumption were also measured in 
the medium, as shown in figures 4.7A and B, respectively. 13C6-glucose levels 
remained higher in the media of the PYGB-suppressed cells, particularly cells 
with sh339 and sh479 constructs. However, 13C-latate released into the medium 
was comparable for all experimental groups. The lower glucose consumption 
elicited by PYGB suppression can be attributed to slower proliferation as well as 
the block in glycogen utilization leading to the accumulation of newly synthesized 
glycogen (Fig. 4.6). In the latter case, glycogen synthesis could be a substantial 
sink for glucose utilization in A549 cells. Taken together, glycogen is an 
important fuel for supporting cancer cell growth. 
4.3.3 PYGB suppression reduces Krebs’ cycle activity 
In order to determine the effect of PYGB suppression on Krebs’ cycle 
metabolism in A549 cells, Krebs’ cycle metabolites and their 13C labeling patterns 
from the 13C6-glucose tracer experiments were quantified using GC-MS. PYGB 
suppression, particularly with the sh479 vector, attenuated the total levels of 
citrate, fumarate, malate, and succinate as shown in figure 4.8. In addition, 13C 
incorporation from labeled glucose into doubly labeled (13C2) Asp, fumarate, 
malate, and succinate were significantly reduced primarily in sh479-suppressed 
cells. These data are consistent with a reduced flux through the Krebs’ cycle in 
sh479-transduced cells (Fig. 4.9). A similar reducing trend was also observed in 
the levels of many amino acids as shown in figure 4.10, again with the sh479 

















Figure 4.7. PYGB suppression reduces glucose consumption 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites of the medium were extracted and measured via 1D proton NMR. Medium13C3-













Figure 4.8. PYGB suppression decreases the level of Krebs’ cycle intermediates 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via GC-MS, and Krebs’ cycle intermediates were 
quantified and normalized to total protein. Data are represented as the fraction of metabolite in 








Figure 4.9. PYGB suppression decreases flux through the TCA cycle 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via GC-MS, and TCA cycle isotopologues were 
quantified and normalized to total protein. Data are represented as the fraction of 13C2-metabolite 
in the designated shPYGB construct over that in shENV.  
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Figure 4.10. PYGB suppression reduces amino acid levsel 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified 
and normalized to total protein. Data are represented as the fraction of metabolite in the 








suppression on amino acids could be related to reduced synthesis of non-
essential amino acids (Fig. 4.11).  
4.3.4 PYGB suppression blocks nucleobase synthesis in A549 cells 
13C incorporation into nucleotides was also measured by FT-ICR-MS to 
determine the effect of PYGB suppression on nucleotide synthesis. The 13C5-
UTP isotopologue corresponds to the fully 13C labeled ribose subunit while 
isotopologues with >5 13C atoms (13C6-8 in Fig. 4.12) represent additional 13C 
incorporation into the uracil ring via the aspartate precursor derived from Krebs’ 
cycle OAA.  Labeling of the ribose subunit was unaffected by the knockdown, 
whereas labeling of the uracil ring was significantly attenuated by PYGB 
suppression, especially for 2 and 3 13C atoms entering the uracil ring, which 
showed a 30-40% reduction in PYGB suppressed cells compared with control 
cells. Again, the sh479 construct had the greatest effect (Fig. 4.12). The 
percentage of unlabeled UTP (13C0-UTP) was also increased by PYGB 
suppression, consistent with reduced incorporation of 13C into the uracil ring and 
with decreased synthesis of its precursor Asp from 13C6-glucose (cf. Fig. 4.9). A 
related sugar nucleotide UDP-N-acetylglucosamine (UDP-GlcNAc) showed 
reduced fractional enrichment in the more extensively labeled isotopologues (e.g. 
13C14-16-UDP-GlcNAc in Fig. 4.13) but increased fractional enrichment in the less 
extensively labeled isotopologues (e.g. 13C5, 13C6, and 13C11-UDP-GlcNAc). 
Unlabeled UDP-GlcNAc was absent by 24 h. 13C5 and 13C6-UDP-GlcNAc 
isotopologues most likely each corresponds to complete enrichment of the ribose 










Figure 4.11. PYGB suppression reduces amino acid synthesis 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified 
and normalized to total protein. Data are represented as the fraction of unlabeled isotopologue 








Figure 4.12. PYGB suppression reduces uracil synthesis 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Nucleotides were extracted and measured via FT-ICR-MS. Fractional distribution of 13C 
isotopologues of UTP were quantified and are represented as the fraction of UTP isotopologue in 















Figure 4.13. Effect of PYGB suppression on UDP-GlcNAc enrichment 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Nucleotides were extracted and measured via FT-ICR-MS. UDP-GlcNAc isotopologues were 
quantified and are represented as the fraction of UDP-GlcNAc isotopologue in the designated 










labeling in both subunits. 13C14-16-UDP-GlcNAc isotopologues then reflect 
labeling in the uracil ring and/or the acetyl unit [92].  Therefore, the reduced 
labeling in the 13C14-16 isotopologues indicates decreased enrichment of the uracil 
and/or acetyl subunits, consistent with attenuated UTP ring synthesis and Krebs’ 
cycle activity (Fig. 2.18). Finally, 13C6-glucose incorporation into ATP showed 
selective attenuation in the fractional enrichment of 13C6-7-ATP relative to 13C5-
ATP with PYGB suppression, again suggesting decreased enrichment in the 
adenine ring (Fig. 4.14). Carbon in the adenine ring is derived from either Gly or 
N10-formyl tetrahydrofolate (THF), the latter of which can be synthesized from Gly 
or Ser and ultimately from glucose (Fig. 4.15). Gly and Ser levels were reduced 
by PYGB suppression (cf. Figs. 4.10, 4.16), which is consistent with a decrease 
in their incorporation into the adenine ring and thus, purine synthesis. Taken 
together, all of the above nucleotide data point to no effect from PYGB 
suppression on ribose incorporation. 
 
4.4 Conclusions 
 This study has shown that lung cancer cells have the capacity to 
synthesize and utilize glycogen in the presence of abundant glucose supply. The 
expression of the fetal form of glycogen phosphorylase (PYGB) and the 
phenotypic consequences of its knockdown on A549 cells demonstrated the 
importance of glycogen utilization for lung cancer cell proliferation, and to some 
extent tumorigenesis. Parallel SIRM investigations reveal perturbations in the 










Figure 4.14. Effect of PYGB suppression on ATP enrichment 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Nucleotides were extracted and measured via FT-ICR-MS. ATP isotopologues were quantified 
and are represented as the fraction of ATP isotopologue in the designated shPYGB construct 
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Figure 4.16. PYGB suppression reduces Gly and Ser synthesis 
5 passages after shPYGB suppression, A549 cells were incubated with 13C6-glucose for 24 h. 
Polar metabolites were extracted and measured via GC-MS, and amino acids were quantified 
and normalized to total protein. Data are represented as the fraction of unlabeled isotopologue 







underlie the phenotypic changes. These results highlight the need for continued 
investigation into the role of glycogen metabolism and PYGB in particular in other 
cancer models and the notion that PYGB is worthy to pursue as a new target for 
cancer chemotherapeutics. Specifically, the individualized lung cancer models 
detailed in chapter 2 are ideal candidates for probing the effects of glycogen 
inhibitors of lung cancer metabolism. We are currently utilizing this approach in 
our ongoing patient study. 
It is worth noting that sh479 had the clearest effect of metabolic disruption 
linked to A549 growth attenuation and reduced colony formation. This effect was 
smaller with sh339 suppression and in all regards anomalous with sh010 as its 
suppression of PYGB was minimal. Furthermore, formation of colonies was 
reduced by PYGB suppression via sh479, suggesting that PYGB is partially 
necessary for tumorigenesis, but likely more important in the setting of tumor cell 
growth and/or survival. 
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CHAPTER 5-CONCLUSIONS 
The central thesis at the core of this study was that the anti-cancer 
mechanism of selenite could be elucidated by utilizing a metabolic approach. In 
order to approach this aim SIRM was extensively used to generate a 
comprehensive profile of the metabolic perturbations that follow when human 
lung cancer is exposed to selenite by using a combination of patient tissue and 
cell-based models. These findings were then followed up with complementary 
methods in order to gain a more finely detailed understanding of the specific 
pathways that may be targeted by selenite. Indeed a number of pathways were 
rigorously examined simultaneously using SIRM experimental design, which 
underscored the viability and necessity of tracer-based design for this level of 
metabolic detail. 
 A principal finding in the initial studies was that the activity of the TCA 
cycle is dramatically reduced by selenite with a concomitant increase in glycolytic 
rate in a cancer-specific manner. This increase in flux through glycolysis is 
accompanied by an increase in lactic fermentation and decrease in flux through 
the pentose phosphate pathway in an effort to meet the compromised energy 
demands of the rapidly growing cancer cells caused by disruption of aerobic 
respiration. These alterations had far-reaching effects in nucleotide and 
hexosamine nucleotide synthesis and utilization. Purine and pyrimidine base 
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synthesis was profoundly impacted by selenite treatment and, to a lesser extent, 
ribose synthesis. Decreased synthesis of the bases was traced back to 
decreased incorporation of Asp, Gly, and Gln carbon and/or nitrogen into the 
purine or pyrimidine rings due primarily to a compromised Krebs’ cycle. This 
attenuation was propagated in the synthesis of UDP-GlcNAc, which in turn has 
downstream implications for the regulation of specific protein targets. Indeed, O-
GlcNAc modification of proteins was extensively decreased in selenite-treated 
cells.  
 Unfortunately, efforts to isolate and further characterize a specific target 
were met with difficulty. By isolating a protein target one could then reassess the 
metabolic profile generated from selenite treatment in order to evaluate possible 
downstream effects of this altered regulatory modification. As O-GlcNAcylation is 
an area of burgeoning interest and relatively few targets (there are many) have 
been thoroughly studied, this approach would be a worthwhile continuation of this 
study, especially in the context of the individualized lung cancer models. 
 A likely source for the observed selenite-induced perturbations in cancer 
metabolism is decreased glutaminolysis. Glutaminolysis was rapidly and 
dramatically inhibited with selenite treatment, and decreased expression of GAC 
was isolated as a probable source. A plausible mechanism for selenite-induced 
cytotoxicity was then postulated that underscored the pivotal role of GLS in 
glutathione synthesis, especially when the cell is compromised by increased 
ROS and the reduction of GSSG becomes overwhelmed. Restoration of A549 
growth upon supplementation with a product of GAC, Glu, was crucial towards 
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solidifying this hypothesis. Furthermore, GAC expression was unchanged in non-
cancer cells, which alludes to a possible mechanism for the cancer-specificity of 
selenite. Examining whether or not Glu supplementation also reverses ROS 
accumulation would be a useful corollary for these experiments. Furthermore, 
assessing the state of ROS with or without Glu supplementation in the 
individualized cancer models would also generate a more compelling story. Also 
what is indicated from this investigation is a thorough dissection of the 
mechanism behind the decrease in GAC expression and why this effect is absent 
in non-transformed cells. 
 Finally, an alternative pathway that was affected by selenite treatment, 
glycogenolysis, was also investigated, abeit less so. Using a combination of 
shRNA PYGB suppression and tracer-based design, I concluded that glycogen 
was an important fuel source for lung cancer, and disruption of its utilization led 
to decreased proliferation as well as tumor formation to a smaller extent. These 
effects of suppression were measured in the context of a host of other metabolic 
alterations that included a decrease in TCA cycle activity as well as nucleobase 
synthesis. These experiments could be greatly augmented by implementation of 
the individualized lung cancer models and a PYGB inhibitor, which is ongoing.  
 The use of individualized lung cancer models was integral towards 
illustrating the translational capabilities of these experiments. A more through 
inclusion of specimens from the ongoing patient study would be an exciting 
project as there is a wealth of clinical data associated with these models. This 
clinical information includes factors like the tumor grade, subtype, and 
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environmental history of the patient from whom it was derived and correlating 
these data to the metabolic profile would be a worthy endeavor.  
 Furthermore, these experiments illustrate the need for continued 
investigation of selenite supplementation for chemopreventive or adjunctive 
chemotherapeutic potential. These efforts are particular important in the context 
of the negative press generated from the failed SELECT trial. Recent analyses of 
traditional Inuit diets have underscored the potential health benefits of selenium-
high diets despite the high levels of mercury and organic pollutants inherent in 
these food sources [93, 94]. The in vivo efficacy of selenite has already been 
demonstrated by the reduction of tumor growth in rodents (reviewed in [20]). 
Clearly, these results point towards exciting future prospects for selenium 
research. Continued accrual and analyses of NSCLC patients as demonstrated 
would likely bolster these overall conclusions. In the future, it is imperative that 
the focus of more targeted studies and/or trials involves seleno-compounds with 
known anti-cancer efficacy over ineffective species, such as selenomethionine. 
 Finally, exposure to the breadth and quality of scientific analyses possible 
by taking advantage of NMR, MS, and molecular biological methods has itself 
been integral for the fruition of this thesis. The opportunities possible for 
metabolic research in the context of tumor biology and beyond are numerous and 
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